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Cancer is the second leading cause of deaths in the United States. This thesis focuses on 
two research project (1) development of novel LC-MS/MS methodology to screen chemicals and 
their metabolites for DNA damaging effects which might eventually lead to cancer and (2) 
development of automated and 3D printed elecrochemical biosensors to detect panels of prostate 
cancer biomarkers for early diagnosis and to differentiate aggressive and non-aggressive versions 
of prostate cancer. 
Chapter 1 gives a brief introduction and describes goals and significance of the thesis. It 
also gives an overview of genotoxicity, DNA damaging events, xenobiotics, and cytochrome 
P450 enzymes and their role in reactive metabolite formation. A brief description of P53 tumor 
suppressor gene and its role in cancer and organ specific cancer is also included. 
ii 
 
Chapter 2 describes the first ever restriction enzyme-assisted LC-MS/MS methodology 
for sequence specific DNA damage by chemical metabolites on exon 7 fragment of P53 gene. It 
describes the importance of structural integrity of large ds-DNA vs small ss-DNA for codon 
specific DNA damage in co-relation tissue specific cancer. 
Chapter 3 shows the effect of cytosine methylation on sequence specificity and rate of 
metabolite adduction on exon 7 fragment of P53 gene. Kinetics of BPDE adduction was 
validated using both LC-MS/MS methodology and molecular modelling. 
Chapter 4 describes the development of magnetic biocolloid technology in a 96 well 
platform to feed DNA damage products to LC-MS/MS to screen multiple cyt P450 enzymes on 
bioactivation of drugs or chemicals and resulting DNA damaging events on P53 gene and 
correlation of results to tissue specific cancer. 
Chapter 5 involves brief overview of prostate cancer and the need for automated low cost 
biosensor in cancer diagnostics. It also describes the developed automated reagent/sample 
cassette and 3D printed user friendly microfluidic devices for protein-based point of care 
diagnostics. 
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Chapter 1 
 
 
 
Introduction 
 
 
 
1-1. Goal & Significance - Part I 
Cancer is characterized by abnormal and uncontrolled growth of cells. Cancer is the second 
leading cause of death in United States of America.1 The number of projected new cancer cases 
in 2016 are 1,685,210 and 59560 cancer deaths.2 Cancer can be caused by external factors like 
tobacco, infections, radiation, alcohol consumption, exposure to environmental pollutants etc., It 
can also be due to internal factors like hormones, inherited gene mutations and immune 
conditions. 
Toxicity screening plays a major role in drug development. Damage to genetic material by 
chemical agents is referred as genotoxicity. Toxicity screening assays are used to assess the 
safety of chemicals/environmental pollutants. Most common tests used commercially include 
Ames test, comet assay and chromosomal aberration/micronucleus assay. These assays are not 
high throughput and do not take into consideration of metabolic pathways that might lead to 
mutagenicity.3,4,5 More over these assays do not give mechanism of DNA damage and no 
molecular level information. Current research focuses on development of high throughput 
toxicity screening assay using liquid chromatography-tandem mass spectrometry to determine 
the possible mutagenicity of chemicals/metabolites. Current method helps in understanding the 
mechanism of covalent interaction between chemical/environmental pollutants and their 
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metabolites to that of DNA. This LC-MS/MS method will also help us to predict the tissue 
specific cancer caused by chemicals/environmental pollutants.  
 
1.2 Cancer etiology 
Cancer can be caused due to both endogenous and exogenous factors.6,7 Endogenous 
factors responsible for cancer include hormonal, estrogen and progesterone in case of breast 
cancer, testosterone in case of prostate cancer8, bacterial infections, genetic inheritance etc., 
Exogenous factors include exposure to environmental pollutants like tobacco smoke, asbestos, 
dietary components, alcohol, radiation, immunosuppression, obesity etc.,9 Cancer is not one 
disease and there are nearly 100 different types of cancer.10 Symptoms and treatment of cancer 
depends on type of cancer and the stage of cancer. Some of the treatments include surgery, 
radiation chemotherapy, hormone therapy, biological therapy and stem cell treatment.11 
 
1.3 Genotoxicity & Types of DNA damage 
Genotoxicity is the property of chemicals to disrupt or damage genetic material which when 
not repaired might lead to cancer. Some of the common events involved in genotoxicity include 
DNA hydrolysis, covalent adduct formation, oxidative DNA damage, abasic site formation, 
DNA strand breaks etc.12  
Thermodynamically DNA hydrolysis is favorable but is extremely slow indicated by the 
very high in half life, Scheme 1.1. This states that DNA is extremely stable in biological 
conditions.13 Spontaneous hydrolysis of DNA accelerated by the presence of enzymes like 
phosphodiesterases, lanthanide ions and metal ions. Deamination of cytosine residues in another 
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mechanism of DNA damage which is enhanced 3-5 times faster upon alkylation on the 5th 
position of the cytosine.14,15  
Scheme 1.1. Mechanism of DNA hydrolysis at neutral pH. B is used to represent presence of 
nucelobases (A, T, G or C).16 
 Hydrolysis of glycosidic bond is often termed as depurination as it more feasible at 
purine bases, guanine and adenine rather than cytosine or thymine. Acid catalyzed hydrolysis of 
glycosidic bond of DNA is as shown in Scheme 1.2. Abasic site formed during depurination are 
cytotoxic and mutagenic.17 
Scheme 1.2. Acid catalyzed hydrolysis of glycosidic bond of DNA. 
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DNA alkylation. Heteroatoms within DNA are preferential targets for DNA alkylation 
N7 position of guanine is the most nucleophilic site in DNA and preferential site of reaction for 
small diffusible alkylating agents. Some bulky chemicals/drugs cannot bind to N7 position of 
guanine due to steric effects and hence bind to exocyclic amine of guanine.18 Some of the 
preferential sites of alkylation in DNA bases are as shown in Scheme 1.3. 
 Scheme 1.3. Structure of DNA nucleobases along with the preferential site of reactivity 
highlighted with an arrow. 
DNA Oxidation. DNA oxidative damage can be either due to cellular metabolic or 
exposure to some toxic environmental chemicals that might result in reactive oxygen species.19 
Some of the ROS species include oxygen free radicals such as superoxide radical anion (O2
-), 
hydroxyl radical (OH•), hydrogen peroxide (H2O2), nitrous oxide (NO) etc., Guanine is the most 
easily oxidized nucleobase due its low oxidative potential.20 
 
1.4 Xenobiotics and Reactive Metabolites 
Xenobiotics are foreign substances that may be chemicals21, drugs, environmental 
pollutants, food additives, hydrocarbons, carcinogens, pesticides found in the organisms but not 
naturally present or anticipated be present.22 Drugs like antibiotics present in human body at 
higher concentrations are also considered to be xenobiotics as they are not produced inside 
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characteristically.23 Xenobiotics are often widely used in context of environmental toxins or 
pollutants as they enter the biological system of humans or animals and undergo changes leading 
to adversative effects.24,25 Xenobiotics are often lipophilic, once they enter the body they are 
transported to other parts of body via blood stream. Due to lipophilic nature, they usually 
accumulated in fat tissues and slowly drain into circulation causes prolonged effects. Once they 
enter the circulation, most of the time they are eliminated form body via detoxification pathways. 
Usually detoxification occurs by metabolism in liver.26 Hepatocytes containing xenobiotic 
metabolizing enzymes (XMEs) convert the fat-soluble chemicals to water soluble products thus 
facilitating their elimination.27 
Xenobiotics or chemicals after entering the human body can be processed by numerous 
pathways that cause the chemicals to interact with specific receptors to have a positive or 
negative effect eventually leading to detrimental effect.28 Under metabolic pathways via 
metabolic enzymes the lipophilic chemicals can be converted to its corresponding products that 
are majorly water soluble.29 These products can either excreted out via kidneys or bile referred as 
detoxification, whereas some of the products are reactive electrophiles that actively bind to 
variety of biomolecules like proteins, lipids and DNA that can potentially lead to toxic effects.30 
Polycyclic Aromatic Hydrocarbons (PAHs) are some of most commonly occurring 
xenobiotics in the environment that cause cancer and other health effects.31 PAHs are also 
referred as polynuclear aromatic hydrocarbons (PNAs) that have only carbons and hydrogens 
and composed of multiple aromatic rings fused together.32 They are usually formed during 
thermal combustion of organic molecules and further recombination. The natural sources of 
PAHs are forest fires, oils seeps, volcanic eruptions etc., whereas anthropogenic sources include 
burning fossil fuel, coal tar, wood, garbage etc. PAHs include 100s of chemicals that are neutral, 
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non-polar with very poor solubility in water and cannot degrade easily under natural 
condition.33,34 Some of the common examples of PAHs are Naphthalene, Anthracene, 
Benzo[a]anthracene, Pyrene, Benzo[a]pyrene (B[a]P) etc.35 Toxicity of all the PAHs are not 
available but US Environmental Protection Agency (EPA) assessed the risks of mixture of PAHs 
and showed all PAHs are almost as potent as  B[a]P which is one of the most potent PAH.36 
Benzo[a]pyrene is one of the most commonly studied carcinogen due its significant presence in 
tobacco smoke, coal tar, grilled meats and its high risk of causing lung cancer.37,38  
Scheme 1.4. CYT P450 mediated conversion of Benzo[a]pyrene (B[a]P) in the presence of 
epoxide hydrolase to benzo[a]pyrenediolepoxide and subsequent covalent binding to exocyclic 
amine of guanine in DNA. 
Benzo[a]pyrene requires metabolic activation prior to reaction with macromolecules like 
DNA and proteins to show their adverse biological effects.39 Oxidation of B[a]P is catalyzed by 
cytochrome P450 (Cyt p450) enzymes and microsomal epoxide hydrolases leading to reactive 
metabolite of B[a]P, which is Benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE), Scheme 
1.4.40 This metabolite of B[a]P is highly carcinogenic and it is classified as class group 1 
carcinogen by International agency for research on cancer (IARC).41 BPDE is highly reactive to 
DNA, forming DNA adducts specifically at guanine residues, Scheme 1.4. It is known that the 
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most abundant DNA adduct is 10-(deoxyguanosin-N2-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydro-
BaP (dG-N2-BPDE).42,43  
Scheme 1.5. CYT P450 catalyzed conversion of NNK (1) to α-hydroxyl metabolite of NNK (2) 
which forms 4-oxo-4-(3-pyridyl)-1-butane-daizohydroxide upon losing a formaldehyde (3), (3) 
reacts with guanine in DNA to form 7-[4-oxo-4-(3-pyridyl)but-1-yl]Gua (4) or O6-[4-oxo-4-(3-
pyridyl)but-1-yl]Guaadducts (5) 
 
Nicotine derived nitrosamine ketone (NNK) is a tobacco specific carcinogen which is 
known to cause lung cancer.44 NNK is also known as 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone which is naturally synthesized in tobacco leaves and enters human body via tobacco 
smoke and nicotine burning.45 NNK also requires metabolic activation to form adducts with 
DNA via Cyt P450 enzymes leading to reactive metabolites. P450 activated metabolite process 
for NNK referred as α-hydroxylation. The hydroxylation reactions at methylene and methyl 
carbons adjacent to N-nitroso groups results in reactive metabolite formation that can potentially 
cause guanine adducts with DNA.46 P450 mediated carbonyl reduction of NNK catalyzed by β-
hydroxy steroid dehydrogenase or carbonyl reductases, produces 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanol (NNAL) a major metabolite of NNK in smokers.47 Mediation of p450 
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metabolic pathway is the most pivotal part of DNA adduct formation and hence no tumor 
formation. As in the absence of NNK α-hydroxylation reactive electrophiles are not generated 
leading to no adduct formation.48 
Aflatoxins are potential cancer causing chemicals that mainly cause hepatocellular 
carcinoma. Aflatoxins are normally produced from molds Aspergillus flavus and Aspergillus 
parasiticus that grows on food, decaying vegetation,dairy, soil etc.49 Aflatoxin B1 (AFB1) is 
considered to be most toxic and causes acute hepatotoxicity and hepatic necrosis that eventually 
leads to cancer.50 AFB1 is usually consumed from contaminated food products, dairy and dairy 
products with aflatoxins from livestock consuming contaminated feed.51 AFB1 requires 
metabolic activation to wield its carcinogenic effect. Metabolic activation of AFB1 to AFB1 exo-
8,9-epoxide via Cyt P450 metabolic pathway almost readily reacts with DNA exclusively at N7 
position of guanine forming AFB1-N7-Gua adducts, Scheme 1.6.52,53 
Scheme 1.6. CYT P450 catalyzed conversion of Aflatoxin B1 to Aflatoxin B1-8,9-epoxide. 
Aflatoxin B1-8,9-epoxide reacts with N7 position of guanine to form covalent adduct. 
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1.5 Cytochrome P450 enzymes 
Cytochrome P450 (CYP P450) enzymes are cysteinato-heme enzymes which play a 
major role in oxidative transformation of xenobiotic compounds. The prosthetic group consists 
of iron (III) protoporphyrin IX covalently linked to the protein by sulfur atom of a proximal 
cysteine ligand.54,55 Common reaction catalyzed by CYP P450 enzymes is as shown in equation 
1. Catalytic cycle of CYP P450 enzymes is as shown in scheme 1.7. Briefly environmental 
pollutant/chemical/drug forms complex with Fe3+ of CYP P450. This complex is reduced by 
CYP reductase at the same time flavoprotein is oxidized using NADPH. An oxygen molecule 
now binds to the reduced complex, oxidizing the drug/substrate and CYP P450 complex. This 
oxidized complex releases the oxidized drug regenerating the CYP P450. 
RH + O2 + NADPH + H
+ → ROH + H2O + NADP+       Equation (1) 
Scheme 1.7. Schematic representation of catalytic cycle of cytochrome P450 enzymes. 
 
1.6 P53 Gene and Organ specific cancer 
P53 gene is tumor suppressor gene located on the short arm of chromosome 17. Tumor 
suppressor genes provide protection against cancer. P53 gene codes for P53 protein that is 
associated with cell cycle regulation and cell death. Mutations within the tumor suppressor gene 
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can lead to faulty P53 protein which in might lead to cancer.56,57 Mutations within the P53 gene 
are often sequence specific in co-relation with organ specific cancer. P53 gene is frequently 
mutated in human cancers (>50% ) 58,59,60 there are demonstrated links between human exposure 
to various carcinogens and specific mutations in the p53 gene leading to the development of 
specific cancers.61 P53 gene has 11 exons and most mutations in the p53 gene occur in the DNA 
binding domain, exons 5 - 8 (Scheme 1.8).62 
 
Scheme 1.8. Exons 5 to 8 of the p53 gene (hotspots are in purple)  
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1.7 Liquid Chromatography Tandem Mass Spectrometry 
Mass spectrometry is a valuable tool in the prediction and characterization of xenobiotics 
and metabolites of xenobiotics. Usually mass spectrometry is coupled with liquid 
chromatography to aid in separation of complex samples and also to increase the sensitivity. 
Liquid chromatography in conjunction with mass spectrometry is used in this thesis to 
characterize and quantitate the amount of DNA damage by various chemicals.  
MS Instruments used in this study include AbSciex QTrap 4000 and ABSciex QSTAR. 
AbSciex QTrap 4000 is a triple quadrupole mass spectrometer mainly used for quantitation and 
AbSciex QSTAR is quadruple time of flight mass spectrometer used for characterization of both 
small molecules and biomolecules. Different modes of mass spectrometer used include product 
ion scan for characterization and multiple reaction monitoring for quantitation. 
Product ion scan is a tandem or MS2 mass spectrometry technique in which a precursor 
ion is selected in the first quadruple, energy applied in the second quadruple and all the product 
ions formed in the third quadruple were scanned and detected in the third quadruple, resulting in 
a MS/MS spectrum as shown in Scheme 1.9. 
Single reaction monitoring is a tandem or MS2 mass spectrometry technique in which a 
precursor ion is selected in the first quadruple, energy applied in the second quadruple to 
fragment the precursor ion and only one fragment selected in the third quadruple. Resulting in an 
chromatogram corresponding to the transition selected. When multiple reaction are monitored 
simultaneously it is called as multiple reaction monitoring. 
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Scheme 1.9. Different modes of tandem mass spectrometry modes used for characterization and 
quantitation.    
 Typically reverse phase chromatography with binary solvent system consisting of 10 mM 
Ammonium acetate as aqueous buffer and methanol/acetonitrile as organic buffer is used for 
separation and MS analysis of small molecules (metabolites of xenobiotics and nucleobase 
adducts) and ion pair reverse phase chromatography with binary solvent system containing 25 
mM triethyl ammonium biocarbonate as aqueous buffer and methanol as organic buffer was used 
for separation and MS analysis of oligonucleotides. 
 
1.8 Summary I 
This thesis focuses on developing high throughput LC-MS/MS methodology for 
screening chemicals for their genotoxic potential and co-relating with the sequence specific 
cancer. Methodology involves reacting chemicals with P53 gene fragments and co-relating the 
sequence specific DNA damage with organ specific cancer. Chapter 2 focuses on determining 
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the chemoselectivity of benzo[a]pyrenediolepoxide on exon 7 of P53 gene fragments and 
differentiating the selectivity and site specificity difference between small ss-oligonucleotides 
with large ds-oligonucleotides. 
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CHAPTER 2 
 
 
Chemical Selectivity of Nucleobase Adduction Relative To In Vivo 
Mutation Sites On Exon 7 Fragment of P53 Tumor Suppressor Gene  
 
 
2-1 ABSTRACT 
Damage to p53 tumor suppressor gene is found in half of all human cancers. Databases 
integrating studies of large numbers of tumors and cancer cell cultures show that mutation sites 
of specific p53 codons are correlated with specific types of cancers. If the most frequently 
damaged p53 codons in vivo correlate with the most frequent chemical damage sites in vitro, 
predictions of organ-specific cancer risks might result. Herein, we describe LC-MS/MS 
methodology to reveal metabolite-adducted nucleobases within codons by LC-
MS/MS for oligonucleotides that are longer than 20 base pairs. Specifically, we used a known 
carcinogen, benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE)  to determine the most 
frequently adducted nucleobases within codons. We used a known sequence of 32 base pairs (bp) 
representing part of p53 exon 7 with 5 possible reactive hot spots. This is the first nucleobase 
reactivity study of a double stranded DNA p53 fragment featuring more than 20 base pairs with 
multiple reactive sites. We reacted the 32 bp fragment with benzo[a]pyrene metabolite BPDE 
that undergoes nucleophilic substitution by DNA bases. Liquid chromatography-mass 
spectrometry (LC-MS/MS) was used for sequencing of oligonucleotide products from the 
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reacted 32 bp fragment after fragmentation by a restriction endonuclease. Analysis of the 
adducted p53 fragment compared with unreacted fragment revealed guanines of codons 248 and 
244 as most frequently targeted, which are also mutated with high frequency in human tumors. 
Codon 248 is mutated in non-small cell and small cell lung, head and neck, colorectal and skin 
cancer, while codon 244 is mutated in small cell lung cancer, all of which involve possible 
BDPE exposure. Results suggest the utility of this approach for screening of adducted p53 gene 
by drugs and environmental chemicals to predict risks for organ specific cancers. 
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2-2. Introduction 
Cancer is the second most common cause of death worldwide.1 Tumor suppressor genes 
in humans provide cancer protection pathways by coding for proteins that control cellular stress 
by inducing cell-cycle arrest, apoptosis and senescence.2 TP53 (or p53) was confirmed as a 
tumor suppressor gene in the 1980s,3 and other tumor suppressor genes such as retinoblastoma 
(RB), Wilms Tumor 1 (WT1), Adenomatosis Polyposis Coli (APC), and p16 have also been 
discovered. The p53 gene encodes p53 protein, which is involved in cell cycle regulation leading 
to cancer protection.4-7 
Tumor suppressor genes can be damaged by xenobiotic chemicals, by their metabolites 
and by radiation. Mutations in the p53 gene have been found in 50% of human cancers.8-12 
Moreover, there are well-documented links between human exposure to various carcinogens and 
specific mutated codons in the p53 gene leading to the development of specific cancers.11-13 Most 
mutations in the p53 gene occur in exons 5 to 8.14,15 
Thus, mutational spectra on the p53 gene are correlated with the incidence of tissue 
specific cancers. For example, data in the p53 database handbook13 show that highly mutated 
reactive hot spots include codons 157, 158, 248, 249 in lung cancer, codon 273 in brain and 
prostate cancer, codons 175, 248 and 273 in breast cancer and codons 175, 282 and 248 in liver 
cancer.13,16  Codon hot spots for reactions of metabolites on the p53 gene have been linked to 
human exposure to particular carcinogens. Specifically, components of tobacco smoke are 
related to lung cancer, tobacco smoke and alcohol to head and neck cancers, aromatic amines to 
bladder cancer, aflatoxine-B1 and hepatitis B virus to liver cancer and ultraviolet light to skin 
cancer. Thus, exposure to specific carcinogens that lead to damage to the p53 gene can be 
correlated with organ-specific cancers. 
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 Scheme 2.1. Exon 7 of the p53 gene. Known highly reactive hotspots 245, 248 and 249 are in 
purple, red and green respectively. Codons 244 and 247 are additional hot spots.13  
 
These relationships between the mutational spectra of p53 to organ-specific cancers are 
clearly indicated in large databases integrating extensive p53 research.13,17 These data include 
genomic studies of patient tumors and cell lines, and show that the p53 gene has 7 reactive hot 
spots between bases 361 and 920 of the reading frame, one in exon 5, one in exon 6, five in exon 
7 (Scheme 2.1), and two in exon 8. Screening of a wide range of carcinogens by assessing 
reactive hot spots on p53 in vitro could identify reactive nucleobases within codons that, if 
correlated with mutational spectra, could be used to predict tissue specific cancers. This sort of 
information is not available for large libraries of potentially reactive compounds or metabolites 
on p53, and is almost non-existent for other tumor suppressor genes.18 New methods for 
screening reactive metabolites for sequence specific tumor suppressor gene damage would be 
valuable tools to assess the potential of new drugs and environmental chemicals for organ-
specific carcinogenicity. 
Mass spectrometry (MS) is a valuable tool for structural analysis of DNA, and LC-MS/MS 
methodologies have been developed over the past decade for sizing and sequencing 
oligonucleotides of up to 20 base pairs (bp).19-23 Harsch, reacted a 10 base pair oligonucleotide 
derived from hypoxanthine-guanine phosphoribosyltransferase gene (HPRT gene) with 
benzo[c]phenanthrene and determined positional isomers in the product.24 Chowdhury and 
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Guengerich reacted a 15 base pair oligonucleotide incorporating hot spot codon 157 on exon 5 of 
p53 gene with mutagenic molecules benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) and 
N-hydroxy-4-aminobiphenyl (N-OH-4ABP) and used MS/MS to determine site reactivity.25  
They also determined C-4 oxidized abasic sites on a 15-mer oligonucleotide.21 Sharma et. al., 
reacted a 17-mer incorporating codon 135 of p53 with 2-acetylAminofluorene (AAF), and 
observed multiple adducts formed from reactions with guanosines.26 Satterwhite et. al., reacted a 
21-mer of p53 containing codon 273 with BPDE.27 Xiong et. al., reacted a 14 mer ds DNA 
containing hot spot codons 157 and 158 with BPDE. Xiong et. al., reacted a 14 mer ds DNA 
containing hot spot codons 157 and 158 with BPDE.19 Sharma et. al., studied a 15 base pair 
DNA containing codon 135 with 2-AAF and 28 and also investigated 14 mer ds DNA with 
codons 157 and 158 29 in reactions with BPDE, AAF and N-OH-4ABP. 
Previous studies have been restricted to ds-oligonucleotides smaller than 20 bp to enable 
direct LC-MS/MS sequencing. The short strands studies thus far contained only a single reaction 
site, and thus did not address relative reactivity between different sites or correlations with 
mutation frequencies in tumors. Further, short strands may exhibit altered structural specificity in 
nucleophilic addition compared to natural tumor suppressor genes that may show tertiary and 
quaternary structural influences on codon reactivity.30-34 
In this paper, we report an LC-MS/MS study of ds fragment of 32 bp of p53 gene exon 7, 
from codon 242 to 253. This fragment exhibits up to 5 reactive hot spots,13-17 and our work 
represents metabolite reactivity of a p53 strand (>20base pairs) with multiple mutation sites. The  
32 bp fragment was chosen to be long enough to mimic higher order structure-reactivity of 
DNA.32 This fragment was reacted with BPDE, the major DNA-reactive metabolite of 
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benzo[a]pyrene,35-37 and then a restriction enzyme was used to cleave the fragment into smaller 
fragments to enable LC-MS/MS sequencing.  
Benzo[a]pyrene is a Group I carcinogen,38 and its reactive metabolite BDPE is implicated 
in lung, head and neck, colorectal and skin cancer. Mutational hot spots within this 32 bp 
fragment include 248, 245, and 249 associated with non-small cell lung cancer, 248, 249 and 244 
for small cell lung cancer, 248 for head and neck cancer, 248 and 245 for colorectal cancer, 248 
and 247 for skin cancer.13,14,15,18 Using the approaches described herein, we found that the most 
frequently BPDE-adducted guanines were within codons 244 and 248, which correlate with 
frequently mutated p53 sites in several cancers. 
 
2-3. Experimental Section 
Caution.  Benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (+/-) (anti) (anti BPDE) is a 
chemical carcinogen. Protective measures including wearing gloves and protective eyewear and 
doing experiments in a closed hood were taken. 
2-3.1. Chemicals and Reagents. Benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (+/-) (anti) 
(anti BPDE) was from National Cancer Institute Chemical Carcinogen Reference Standard 
Repository. Triethylammonium bicarbonate (TEAB, 1.0 M, pH 8.4-8.6) and 4-nitrobenzyl 
alcohol were from Sigma-Aldrich. Custom made single stranded DNA oligomers and the 32-
base pair oligonucleotide were from Sigma-Aldrich. HPLC grade solvents, methanol, 
tetrahydrofuran and water were from Fischer Scientific. Restriction enzyme, NIaIII was from 
New England Biolabs. 
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2-3.2. Reactions of Oligonucleotides with BPDE. Reactions with BPDE were done with 4 single 
stranded (ss) oligonucleotides and the double stranded (ds) 32 bp portion of P53 gene representing codons 
242 to 253. 0.1 nmol of each of the 4 ss oligonucleotides were treated with 100 nmol BPDE in a reaction 
volume of 150 µL at 37°C for 48 hours in dark, 10 mM Tris buffer, pH 7.4. 2.5 µmol of ds 32 bp 
fragment was reacted with 0.1 µmole of BPDE in volume of 150 µL at 37°C for 48 hours in dark, 10 mM 
Tris buffer, pH 7.4. A minimum of three replicates of DNA and BPDE reactions were done. 
Scheme 2.2 Protocol for sample preparation of 32-base pair p53 fragment reacted with BPDE 
involving steps: (1) removal of excess BPDE from DNA reaction mixture; (2) restriction enzyme 
treatment to cut DNA into smaller fragments; (3) protein removal; (4) desalting and (5) rapid 
heating and cooling to give ss DNA.  
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2-3.3. Removal of excess BPDE. ss DNA fragments were extracted from the BPDE-ss DNA 
mixture by extracting with 150 µL of ethylacetate for three times. DNA was recovered from the 
aqueous phase. Samples were then dried and reconstituted in 100 µL of pure water to make a 
final concentration of 1 µM ss DNA.  
For the ds-DNA-BPDE mixtures, Millipore 3000 Dalton mass cutoff filter vials were 
used to remove unreacted BPDE (Scheme 2.2). Reaction mixture from above was put into a 3000 
Da mass cutoff filter, (catalog # UFC500396) and centrifuged at 13000 rpm for 30 min. ds-DNA 
was retained on the filter, while the smaller BPDE molecules pass through. The filter was then 
removed, inverted and placed into a new centrifuge vial, and centrifuged for another 30 min. 
Approximately 50 µL of the DNA solution was recovered. Recovered solutions of ds 
oligonucleotides were subjected to restriction enzyme treatment (Scheme 2.2). 
 
2-3.4 Restriction enzyme treatment on ds DNA. Approximately 50 µg (2.5 µmol) of DNA 
was recovered from above step. 50 units (5 µL) of restriction enzyme, NIaIII was added to 50 µg 
of the ds 32 bp oligonucleotides to which 20 µL of 10X NE buffer supplied by New England 
mixture was incubated at 37 °C for 8 hours. The resulting solution is mixture of DNA fragments, 
protein and salt from the NE reaction buffer given by the manufacturer. 
 
2-3.5 Removal of Proteins from DNA-Protein-Salt mixture. Proteins were removed from the DNA 
samples by extraction using 200 µL of water-saturated phenol/chloroform/isoamylalcohol, 25/24/1. Each 
extraction step involves vortexing on a rotor for 10 min followed by centrifugation for 10 min prior to 
aqueous phase collection. DNA in the aqueous phase was collected and the extraction procedure was 
repeated twice more. Further extraction of DNA contained in the aqueous phase was done twice with 200 
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µL of water-saturated chloroform/isoamylalcohol, 24/1. Finally the aqueous phases were combined and 
organic phase was discarded. The resulting sample containing DNA and salt was approximately 200 µL. 
 
  
2-3.6 Desalting. Solid phase extraction (SPE) was performed to remove salt from DNA-salt 
mixtures to obtain samples suitable for LC-MS/MS analysis. Waters Oasis HLB cartridges were 
used for desalting. The method involves initial equilibration of the cartridge with methanol and 
water. Sample was loaded and then washed with 5% methanol in water to remove salts followed 
by elution with 100 % methanol. The resultant DNA sample was dried and reconstituted in 100 
µL pure water. The ds DNA samples were heated and cooled rapidly to convert ds DNA to ss 
DNA and stored at -20 ºC until LC-MS/MS analysis. 
 
2-3.7 LC-MS/MS analysis. A Waters Capillary LC-XE (Milliford, MA) chromatograph with a 
Gemini C-18 column (0.3 mm X 150 mm, 5µ for ds DNA fragments & 0.5 mm X 150 mm, 3µ 
for ds DNA fragments) and photodiode array detector were used.  Separation featured a binary 
solvent consisting of A - 25 mM TEAB and B - methanol. Separation was achieved with a 
gradient of 0 % to 10% B for 10 min followed by increase from 10 to 50 % B for 100 min and 50 
to 100 % B for the final 10 min at flow rate 10 µL/min. m-Nitrobenzylalcohol increases signal 
intensity and charge states of oligonucleotide fragments in negative mode, which enhances the 
fragmentation of oligonucleotides in tandem mass spectrometry.39 Thus, 0.1 % m-nitrobenzyl 
alcohol was infused at a flow rate of 3 µL/min to mix with the LC flow post-column using a 
three way connector before entering the mass spectrometer to produce supercharged 
oligonucleotide fragments. 
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ss-DNA fragments were analyzed with an AB Sciex Qtrap 4000 mass spectrometer 
interfaced to the capillary LC. Enhanced multiple charge (EMC) mode for sizing (molecular 
weight measurement) and enhanced product ion mode (EPI) for sequencing of ss-DNA 
fragments in negative mode were employed. Potentials -4500 V (ion spray voltage), 130 V 
(declustering potential), -60 eV (collision energy), and 20eV (collision energy spread) were used 
while GS1, GS2, and temperature were kept at 35, 20, and 350°C, respectively. 
For analysis of ds-DNA samples, an AB Sciex QSTAR mass spectrometer was interfaced 
with the capillary LC. Negative ion mode with a -4500 V ion spray voltage, -130 V declustering 
potential and 300°C temperature was used. DNA fragments were subjected to time of flight mass 
scan (TOF-MS) mode for sizing of unreacted and adducted DNA fragments and product ion scan 
mode was used at -45 eV collision energy for MS/MS sequencing. Only singly adducted 
fragments were discussed in this study. 
 
2-4. Results 
Initial studies centered on reacting single-strand fragments GGCGGCATG (ss-DNA 
Fragment 1), including hot spot codon 244 and 245, AACCGGAGGCCCATCCTCA (ss-DNA 
Fragment 2), including hot spot codon 248 and 249, TGAGGATGGGCCTCCGGTTCATG (ss-
DNA Fragment 3, complementary to fragment 2) and CCGCCCATG (ss-DNA Fragment 4, 
complementary to fragment 1) with BPDE to optimize the LC-MS/MS methodology without 
using the  restriction enzyme.  
Our protocol for the 32 base pair exon 7 fragment involves reacting p53 oligonucleotide 
sequences with BPDE, then using restriction enzymes to cut the reacted fragment into smaller 
fragments suitable for LC-MS/MS (Scheme 2.3). Our 32 bp exon 7 fragment extends from codon 
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242 to 253 and includes possible reactive hot spots at codons 244, 245, 247, 248 and 249 related 
to the various cancers described above. All codons contain guanine except 247 (ACC), which 
contains a possible reactive adenine. Within this sequence, codon 248 is the most frequently 
mutated in all cancers.13 Codons 245, 248 and 249 are adducted for most cancers related to 
BPDE, which adds to DNA bases by nucleophilic substitution. Our 32 base pair fragment is a 
combination of ss-DNA fragment 1 and ss-DNA fragment 2 with four additional bases CATG 
added before the ss-DNA fragment 1. This was done in order to eliminate the possibility of 
having terminal guanines with enhanced reactivity. 
 
Scheme 2.3. (A) Sample preparation for LC-MS/MS sizing and sequencing of fragment. (B) 32 
bp exon 7 fragment showing cut points for restriction enzyme NIaIII along with resulting 
fragments obtained. 
In order to sequence products of 32 base pair oligonucleotide reactions with BPDE by 
LC-MS/MS, we used the restriction enzyme NlaIII, which cuts DNA after the sequence CATG 
(Scheme 2.3). For our 32 bp fragment, this results in two fragments of 13 and 19 bases that are 
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double stranded except for 4 bases at their ends (Scheme 2.3B). 13 mer was obtained instead of 
the expected 9 mer since the efficiency of restriction enzymes to cut the dsDNA decreases 
drastically when the recognition site in closer to the 5’ end. A minimum of 3-4 extra bases 
flanking the recognition site on the 5’ prime end was required for restriction enzyme to act on ds-
DNA.40 These two ds-fragments were rapidly heated and cooled to give in 4 ss-oligonucleotide 
fragments (Scheme 3A). 
We used enhanced multiple charge scanning to size the ss-oligonucleotides, followed by 
collision-induced dissociation (CID) MS/MS for sequencing. CID of oligonucleotides shows a 
characteristic fragmentation pattern (Scheme 2.4) featuring an-bn and wn ions.
41-44 Adduction of 
BPDE to specific nucleobases within codons was monitored by comparing un-adducted 
oligonucleotides to those reacted with BPDE, and detecting the difference in m/z of the an-bn and 
wn ions. 
Scheme 2.4. Collision Induced Dissociation (MS/MS or tandem MS) of DNA fragments 
resulting in the generation of wn and an-bn ions. 
Enhanced multiple charge scans (EMC) were used to determine the m/z of standard and 
BPDE-adducted DNA fragments that have an additional mass of 302.323. Expected multiple 
charged species possible were calculated using the online database Mongo oligomass 
calculator.45  
We first present results for the ss-Fragments. Possible m/z for standard and singly adducted ss-
DNA fragments are as shown in Table 1 for ss-Fragment 1. With the ionization conditions used, 
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we observed an m/z of 1388.9 for unreacted ss-Fragment 1 with a charge of -2 and m/z of 1540.5 
for the reacted fragment indicating a singly adducted strand also with charge -2. Multiple peaks 
for a single fragment ion were observed due to isotopic distribution, (see Figure 2-1, fragment 
ion 1540.5). 
 
Table 2-1: Calculated multiple charged species for standard and single adducted ss-Fragment 1. 
 
ss-Fragment 1 : GGCGGCATG 
Charge 
m/z 
Standard Singly Adducted 
-1 2778.854 3081.177 
-2 1388.923 1540.084 
-3 925.612 1026.386 
-4 693.957 769.538 
-5 554.964 615.429 
-6 462.302 512.689 
-7 396.115 439.304 
-8 346.474 384.264 
 
Figure 2-1. Isotopic distribution pattern for ss-DNA Fragment 1, m/z 1540.5 z=-2, measured on 
a Qtrap mass spectrometer 
Extracted ion chromatogram of a selected ion as a function of retention time of singly 
adducted ss-DNA fragment 1 of m/z 1540.5 shows (Figure 2-2A) that there is a possibility of 2 
positional isomers for the singly adducted ss-Fragment 1 at retention times 38.67 and 43.75 min. 
CID of fragment ion 1540.5 for Peak I is as shown in Figure 2-2B and for Peak II in Figure 2-2C.  
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Figure 2-2. LC-MS of ss-DNA fragment 1 (A) Extracted ion chromatogram for fragment m/z 
1540.5 representing z = -2 singly adducted fragment 1. (B) MS/MS spectrum of singly adducted 
BPDE ss- DNA fragment 1, m/z 1540.5 for peak I eluting at 38.67 min and (C) MS/MS of peak 
II eluting at 43.75 min. (1540.7 or 1540.8 m/z was observed instead of 1540.5 due to isotopic 
distribution) 
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 Differences in m/z of a-b and w ions between the standard ss-DNA fragment 1 and the 
singly adducted DNA fragment help locate the exact reacted position on a given 
oligonucleotide.46-48 Table 1 summarizes fragment ions obtained for standard ss-DNA fragment 
1, singly adducted ss-fragment 1 for peaks I and II. Red numbers indicate those ions increased in 
mass by 302.32 from adducting with BPDE compared to the unreacted fragment. 
MS/MS spectrum for peak I of singly adducted ss-fragment 1 (Figure 2-2B) reveals increase 
in mass of all the ions from a3-b3 to a6-b6 and w8 compared with that of unreacted ss DNA 
standard (Table 2-2). This indicates covalent binding of BPDE on the second G base, 
GG*CGGCATG. This is additionally confirmed by the presence of ion a2-b2 with an m/z of 
426.2- and all ions from w1 to w7 with m/z the same as that of the standard. 
 
Table 2-2. Fragment ions for standard ss-DNA Fragment 1 of m/z 1388.9 and singly adducted 
BPDE Fragment 1 ion with m/z of 1540.5 from LC-MS/MS.  
Fragment Ion 
m/z 
Standard Peak I Peak II 
a2-b2 [426.2]
- [426.2]- [426.2]- 
a3-b3 [755.5]
- [1057.5]- [755.4]- 
a4-b4 [1044.7]
- [1347.7]- [1044.3]- 
a5-b5 [1373.5]
- [1676.9]- [1373.8]- 
w1 [346.2]
-1 [346.2]- [648.3]- 
w2 [650.3]
- [650.3]- [952.5]- 
w3 [963.4]
- [963.4]- [1265.5]-2 
w4 [1252.8]
- [1252.5]- [1555.8]- 
w5 [1582.0]
- n/d [1884.7]- 
w6 n/d n/d n/d 
w7 [1099.7]
-2 [1099.9]-2 [1251.6]-2 
w8 [1263.3]
-2 [1416.1]-2 [1415.7]-2 
 
MS/MS spectrum for peak II of singly adducted ss- fragment 1 (Figure 2-2C) reflects 
increases in m/z for all the w ions compared to unreacted standard (Table 2-2). This indicates 
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covalent binding of BPDE to the last G base, GGCGGCATG*, which was supported by all a-b 
ions having m/z similar to unreacted standard.  
 
Figure 2-3. LC-MS/MS of ss-DNA fragment 2 (A) Extracted ion chromatogram of singly 
adducted ss-DNA Fragment 2 fragment, m/z 1511.0. (B) MSMS spectra of fragment ion 1511.0 
showing the obtained an-bn and wn ions. Ions with m/z similar to standard are shown in green and 
ions with increased m/z shown in red. 
 Singly adducted fragment of ss-DNA Fragment 2 has an m/z of 1511.0 with a charge of -4. 
Extracted ion chromatogram of 1511.0 is as shown in Figure 2-3A. XIC of 1511.0 show one major 
peak indicating that there is one major adduct on ss-DNA Fragment 2. MSMS spectra for singly 
adducted ss-DNA Fragment 2, m/z 1511.0 is as shown in Figure 2-3B.  All an-bn ions up to a9-b9 have 
m/z similar to that of standard. Increase in m/z was observed for a10-b10. This indicates that the 
possible modification is on base 9, (AACCGGAGG*CCCATCCTCA). This was further confirmed 
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with wn ions. Increase in m/z for w11, w12, and w13 ions and ions below w10 have m/z similar to that of 
standard. Table 2-3 shows the m/z for standard and adducted ss-DNA Fragment 2. 
 
Table 2-3. Calculated m/z for standard and singly adducted DNA fragments of ss-DNA 
Fragment 2. (m/z highlighted in red were the ions with increased m/z compared to that of 
standard corresponding to BPDE adducted) 
 
Singly adducted ss-DNA Fragment 4 has m/z of 1480.2 with a charge of -2. Extracted ion 
chromatogram (XIC) of 1480.2 is as shown in Figure 2-4A. XIC of 1480.2 showed three major 
peaks indicating that there are three major adducts on ss-DNA Fragment 4, the complement of 
fragment 1. 
MSMS spectra for singly adducted ss-DNA Fragment 4, m/z 1480.2 is as shown in 
Figure 2-4B for Peak 1.  All an-bn ions up to a3-b3 have m/z similar to that of standard. Increase 
in m/z was observed for a4-b4, a5-b5 and a6-b6. This indicates that the possible modification is on 
base 3, (CCG*CCCATG). This was further confirmed with wn ions. Increase in m/z for w7 and 
Fragment Ion 
m/z 
Standard Singly adducted 
a
7
-b
7
 [979.4]-2 [979.4]-2 
a
8
-b
8
 [1136.1] -2 [1136.1]-2 
a
9
-b
9
 [1301.0] -2 [1301.0]-2 
a
10
-b
10
 [1465.5] -2 [1616.7]-2 
a
11
-b
11
 [1073.0] -3 [1761.4]-2 
a
12
-b
12
 [1169.4] -3 [1906.2]-2 
w
8
 [1204.4]-2 [1204.4]-2 
w
9
 [1349.1]-2 [1349.1]-2 
w
10
 [1492.9] -2 [1493.2]-2 
w
11
 [1657.5] -2 [1808.8]-2 
w
12
 [1214.4] -3 [1973.4]-2 
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w8 ions and all ions below w6 have m/z similar to that of standard. Table 2-4 shows the m/z for 
standard and adducted ss-DNA Fragment 4. 
 
Figure 2-4. LC-MS/MS of ss Fragment 4 (A) Extracted ion chromatogram of singly adducted ss 
Fragment 4 fragment with m/z 1480.2. (B) MSMS spectra of Peak 1 (C) MSMS spectra of Peak 
2 (D) MSMS spectra of Peak 3 showing the obtained an-bn and wn ions. Ions with m/z similar to 
standard are shown in green and ions with increased m/z shown in red. 
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MSMS spectra for singly adducted ss-DNA Fragment 4, m/z 1480.2 is as shown in 
Figure 2-4C for Peak 2.  All an-bn ions up to a7-b7 have m/z similar to that of standard. Increase 
in m/z was observed for a8-b8. This indicates that the possible modification is on base 7, 
(CCGCCCA*TG). This was further confirmed with wn ions. Increase in m/z for w3, w4, w5, w6, 
w7 and w8 ions and ions w1 and w2 have m/z similar to that of standard. Table 2-4 shows the m/z 
for standard and adducted ss-DNA Fragment 4.  
 
Table 2-4: Calculated m/z for standard and singly adducted DNA fragments of ss-DNA 
Fragment 4. (m/z highlighted in red were the ions with increased m/z compared to that of 
standard corresponding to BPDE adducted) 
 
MSMS spectra for singly adducted ss-DNA Fragment 4, m/z 1480.2 is as shown in 
Figure 2-4D for Peak 3.  All an-bn ions have m/z similar to that of standard. This indicates that 
the possible modification is on base 9, (CCGCCCATG*). This was further confirmed with wn 
Fragment 
m/z 
Standard Peak1 Peak 2 Peak 3 
a
2
-b
2
 [386.2]- [426.2]- [386.2]- [386.2]- 
a
3
-b
3
 [675.4]-  [675.4]- [675.4]- [675.4]- 
a
4
-b
4
 [1004.4]-  [1306.6]- [1004.4]- [1004.4]- 
a
5
-b
5
 [1293.8]- [1595.6]- [1293.8]- [1293.8]- 
a
6
-b
6
 [1583.0]- [1885.5]- [1582.5]- [1582.6]- 
a
7
-b
7
 [1872.2]-2 n/d n/d [934.5]-2 
a
8
-b
8
 [1092.2]-2  n/d [1244.7]-2 n/d 
w
1
 [346.2]-2 [346.2]-2 [346.2]-2 [648.23]- 
w
2
 [650.4]- [650.3]- [650.3]- [952.4]- 
w
3
 [963.6]- [963.4]- [1265.5]- [1265.6]-2 
w
4
 [1252.8]- [1252.5]- [1555.5]- [1554.6]- 
w
5
 [1541.9]- [1542.9]- [1844.7]- [1843.8]- 
w
6
 [1831.2]- [915.0]-2 [1066.6]-2 [1066.6]-2 
w
7
 [1079.7]-2 [1230.9]-2 [1231.1]-2 [1231.0]-2 
w
8
 [1224.3]-2 [1375.7]-2 [1375.6]-2 [1375.5]-2 
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ions showing increase in m/z for all wn ions. Table 4 shows the m/z for standard and adducted 
fragment 4. 
Singly adducted ss-DNA Fragment 3 has m/z of 1935.5 with a charge of -4. Extracted ion 
chromatogram of 1935.5 is as shown in figure 2-5A. XIC of 1935.5 show one major peak 
indicating that there is one major adduct on ss-DNA Fragment 4. MSMS spectra for singly 
adducted ss-DNA Fragment 3, m/z 1935.5 is as shown in Figure 2-5B.  Increase in m/z for wn 
ions w20, w21, w22 and w23 indicate that the modification is on 5
th base 
(GTGAG*GATGGGCCTCCGGTTCATG). 
 
Figure 2-5. LC-MS/MS of ss-DNA Fragment 3 (A) Extracted ion chromatogram of singly 
adducted ss-DNA Fragment 3, m/z 1935.5. (B) MSMS spectra of fragment ion of m/z, 1935.5 
charge -4 showing the obtained an-bn and wn ions. Ions with m/z similar to standard are shown in 
green and ions with increased m/z shown in red 
 
41 
 
 
 
Table 2-5. Standard single stranded DNA fragments with their corresponding base adducted in 
comparison with the hot spot database.13  
Standard 
ss-DNA 
Sequence 
LC-MS/MS DATA Common Hot Spots 
from Database13-15,18  Base adducted Codon 
Fragment 1 GGCGGCATG 
GG*CGGCATG 244
b
 244b, 245a,d 
GGCGGCATG* 246 244b, 245a,d 
Fragment 2 
AACCGGAGGC
CCATCCTCA 
AACCGGAGG*C
CCATCCTCA 
249
a,b
 248
a,b,c,d,e
, 249
a,b,
 
Complementary Strands 
Fragment 3 
GTGAGGATGGGCCTCCGGTTC
ATG 
GTGAG*GATGGGCCTCCGGTTC
ATG 
Fragment 4 
CCGCCCATG 
 
CCG*CCCATG 
CCGCCCA*TG 
CCGCCCATG* 
 
Note: Possible cancers due to BPDE a. Non Small Cell lung cancer, b. Small Cell lung cancer, c. 
Head and Neck cancer d. Colorectal cancer, e. Skin Cancer 
 
 
Scheme 2.5. A) Protocol for reaction of 32 base pairs DNA fragment with BPDE followed by 
restriction enzyme treatment and possible fragments. B) Example of bond breaking between O 
and P if restriction enzyme acts between G and A. 
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After establishing and optimizing reproducible methodology on the standard single 
stranded DNA fragments, the 32 bp ds-p53 exon 7 fragment, which is a combination of 
fragments 1 and 2 along with the complementary strand, was reacted with BPDE. Four bases, 
CATG were added to the front of fragment 1 to avoid terminal guanines. The sequence added is 
consistent with the exon 7 sequence. Excess BPDE was removed using mass cutoff filters, then 
the aqueous extract was treated with restriction enzyme NIaIII to cut the fragment into smaller 
fragments suitable for LC-MS (Schemes 2.3 and Scheme 2.5). Subsequently, heating and rapid 
cooling gave the four single stranded fragments. The m/z values possible for the standard four 
single stranded fragments and the single adducted fragments are shown in Table 2-6. 
 
Table 2-6. Calculated m/z for standard and singly adducted DNA fragments obtained after 
restriction enzyme treatment of 32 base pair DNA (A) Fragment 1 (B) Fragment 2 (C) Fragment 
3 (D) Fragment 4. m/z highlighted in red were the ions detected in MS spectrum. 
(A) Fragment 1
5’-CATGGGCGGCATG-OH
Charge Standard Single adducted
-1 4014.656 4316.979
-2 2006.824 2157.986
-3 1337.546 1438.320
-4 1002.908 1078.489
-5 802.124 862.589
Charges up to -12 are possible only few 
shown here
(B) Fragment 2
P-AACCGGAGGCCCATCCTCA-OH
Charge Standard Single adducted
-1 5821.771 6124.094
-2 2910.381 3061.543
-3 1939.918 2040.692
-4 1454.686 1530.267
-5 1163.547 1224.012
Charges up to -18 are possible only few 
shown here
(D) Fragment 4
OH-GTACCCGCC-P
Charge Standard Single adducted
-1 2738.759 3041.082
-2 1368.875 1520.037
-3 912.247 1013.021
-4 683.933 759.514
Charges up to -8 are possible only few shown 
here
(C) Fragment 3
OH-GTACTTGGCCTCCGGGTAGGAGT-OH
Charge Standard Single adducted
-1 7110.654 7412.977
-2 3554.823 3705.985
-3 2369.546 2470.320
-4 1776.907 1852.488
-5 1421.324 1481.789
-6 1184.269 1234.656
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Figure 2-6. LC-MS of ds-32 bp exon 7 fragment: (A) Extracted ion chromatogram of singly 
adducted fragment 2, m/z 1530.3, z = -4. (B) MS/MS spectrum of 1530.3 showing an-bn and wn 
ions. Ions with m/z similar to standard labeled in green and ions with increased m/z in red. 
In order to determine sequence specificity on the entire 32 bp fragment, collision induced 
dissociation (CID or MS/MS) was performed on all possible single adducted oligonucleotide 
fragments. Singly adducted fragment 2 is described here as the fragment containing hot spot 248 
and 249 active for a number of cancers.13-15,18 Singly adducted fragment 2 upon MS ionization 
produced a ion of m/z 1530.3 with z = -4. The extracted ion chromatogram (XIC) of m/z 1530.3 
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(Figure 2-6A) gave only one major peak indicating that there is one major adduct on the singly 
adducted fragment 2 of the reacted 32 bp fragment.  
MS/MS spectra for singly adducted fragment 2, m/z 1530.3, (Figure 2-6B) shows all an-
bn ions up to a5-b5 have m/z similar to that of unreacted standard. An increase in m/z of 302.323 
(z = -1) was observed for a6-b6, a7-b7, a8-b8. This suggests that the possible modification is on 
base 5, (AACCG*GAGGCCCATCCTCA). This was confirmed by increases in m/z for w15 and 
w16 ions, while all w ions below w14 have m/z similar to that of unreacted standard (Table 2-7). 
 
Table 2-7. Fragment ions for unadducted fragment 2 m/z 1454.6 and singly adducted fragment 2 
m/z 1530.3 of the ds-32 bp exon 7 fragment from LC-MS/MS  
Fragment ion 
m/z 
Unadducted Singly Adducted 
a2-b2 [490.2]
- [490.2]- 
a3-b3 [803.3]
- [803.3]- 
a4-b4 [1092.4]
- [1092.4]- 
a5-b5 [1381.5]
- [1381.5]- 
a6-b6 [1710.6]
- [1005.8]2- 
a7-b7 [1019.4]
2- [1170.4]2- 
a8-b8 [1176.2]
2- [1327.0]2- 
w9 [1348.0]
2- [1348.0]2- 
w10 [1492.7]
2- [1492.5]2- 
w11 [1657.7]
2- [1657.7]2- 
w12 n/d n/d 
w13 [1318.4]
3- [1318.4]3- 
w14 [1428.3]
3- [1428.3]3-  
w15 [1538.0]
3- [1639.2]3- 
w16 [1634.5]
3- [1735.8]3- 
 
Similar experiments were done on the other singly adducted fragments obtained from the 
reacted ds-32 bp fragment, giving fragment 1 (m/z 1437.8, z = -3), Fragment 3 (m/z 1012.7, z = -3) 
and fragment 4 (m/z 1234.9, z = -6). MS/MS spectra are shown in supporting information file (Figure 
2-7, 8 & 9 & Table 2-8, 9 & 10), and results summarized in Table 2-11. These results were identical 
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when the chemical reaction was done in the same buffer containing 10 mM NaCl, to see if reaction 
conditions would affect the specificity (Figure 2-10). 
Figure 2-7. LC-MS of ds-32 bp exon 7 probe: (A) Extracted ion chromatogram of singly adducted 
fragment 1, m/z 1438.2. (B) MSMS spectra of Peak 1 (C) MSMS spectra of Peak 2 showing the 
obtained an-bn and wn ions. Ions with m/z similar to standard are shown in green and ions with 
increased m/z shown in red. 
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Table 2-8. Calculated m/z for standard and singly adducted DNA Fragment 1. (m/z highlighted 
in red were the ions with increased m/z compared to that of standard corresponding to BPDE 
adducted) 
Fragment ion 
m/z 
Unadducted Peak 1 Peak 2 
a
4
-b
4
 [1003.4]- [1003.4]- [1003.4]- 
a
5
-b
5
 [1332.5]- [1332.5]- [1634.7]- 
a
6
-b
6
 [1661.6]- [1963.7]- [1963.7]- 
a
7
-b
7
 [995.2]-2 [1145.9]-2 [1145.9]-2 
a
8
-b
8
 [1139.5]-2 [1290.5]-2 [1290.5]-2 
a
9
-b
9
 [1304.1]-2 [1455.7]-2 [1455.1]-2 
a
10
-b
10
 [1468.5]-2 [1619.6]-2 [1619.6]-2 
w2 [650.2]- [650.2]- [650.2]- 
w3 [963.3]- [963.3]- [963.3]- 
w4 [1252.5]- [1252.5]- [1252.5]- 
w5 n/d n/d n/d 
w6 [954.8]-2 [954.8]-2 [954.8]-2 
w7 [1099.4]-2 [1099.4]-2 [1099.4]-2 
w8 [1263.9]-2 [1263.9]-2 [1263.9]-2 
w9 [1428.7]-2 [1581.5]-2 [1428.5]-2 
w10 [1593.3]-2 [1745.4]-2 [1163.1]-3 
 
Singly adducted fragment 1 has an m/z of 1438.2 with a charge of -3. Extracted ion 
chromatogram of 1438.2 is shown in Figure 2-7A. XIC of 1223.8 show two major peaks 
indicating that there are two major adduct on Fragment 1. 
MSMS spectra for singly adducted Fragment 1, m/z 1438.2 is as shown in Figure 2-7B 
for Peak 1.  All an-bn ions up to a5-b5 have m/z similar to that of standard. Increase in m/z was 
observed for a6-b6, a7-b7, a8-b8. This indicates that the possible modification is on base 5, 
(CATGG*GCGGCATG). This was further confirmed with wn ions. Increase in m/z for w9 and 
w10 ions and all ions below w8 have m/z similar to that of standard. Table showing the m/z for 
standard and adducted Fragment 1 is as shown in Table 2-8. 
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MSMS spectra for singly adducted Fragment 1, m/z 1438.2 is as shown in Figure 2-7C for Peak 2.  
All an-bn ions up to a5-b5 have m/z similar to that of standard. Increase in m/z was observed for a5-b5, 
a6-b6, a7-b7 and a8-b8. This indicates that the possible modification is on base 4, 
(CATG*GGCGGCATG). This was further confirmed with wn ions. Increase in m/z for w10 ion and 
all ions below w9 have m/z similar to that of standard. Table showing the m/z for standard and 
adducted Fragment 1 is as shown in Table 2-8. 
Figure 2-8. LC-MS of ds-32 bp exon 7 probe: (A) Extracted ion chromatogram of singly adducted 
Fragment 4, m/z 1012.6. (B) MSMS spectra of m/z 1012.6 showing the obtained an-bn and wn ions. 
Ions with m/z similar to standard are shown in green and ions with increased m/z shown in red. 
 
Singly adducted Fragment 4 has an m/z of 1012.6 with a charge of -3. Extracted ion 
chromatogram of 1012.6 is as shown in Figure 2-8A. XIC of 1012.6 show one major peak 
indicating that there is one major adduct on Fragment 4. MSMS spectra for singly adducted 
Fragment 4, m/z 1012.6 is as shown in Figure 2-8B.  All an-bn ions up to a3-b3 have m/z similar 
to that of standard. Increase in m/z was observed for a4-b4, a5-b5, a6-b6, a7-b7 and a8-b8. This 
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indicates that the possible modification is on base 3, (CCG*CCCATG). This was further 
confirmed with wn ions. Increase in m/z for w7 ion and all ions below w6 have m/z similar to that 
of standard. Table showing the m/z for standard and adducted Fragment 4 is as shown in Table 
2-9. 
 
Table 2-9. Calculated m/z for standard and singly adducted Fragment 4. (m/z highlighted in red 
were the ions with increased m/z compared to that of standard corresponding to BPDE adducted) 
 
Singly adducted Fragment 3 has an m/z of 1234.4 with a charge of -6. Extracted ion 
chromatogram of 1234.4 is as shown in Figure 2-9A. XIC of 1012.6 show one major peak 
indicating that there is one major adduct on Fragment 3. MSMS spectra for singly adducted 
Fragment 3, m/z 1234.4 is as shown in Figure 2-9B.  All an-bn ions up to a5-b5 have m/z similar 
to that of standard. Increase in m/z was observed for a6-b6, a7-b7 and a8-b8 and w19. This indicates 
that the possible modification is on base 5, (TGAGG*ATGGGCCTCCGGTTCATG). Table 
showing the m/z for standard and adducted Fragment 4 is as shown in Table 2-10. 
Fragment ion 
m/z 
Unadducted Singly Adducted 
a
2
-b
2
 [466.1]- [466.1]- 
a
3
-b
3
 [755.2]- [755.2]- 
a
4
-b
4
 [1084.8]- [1386.4]- 
a
5
-b
5
 [1373.8]- [837.2]-2 
a
6
-b
6
 [1663.0]- [981.8]-2 
a
7
-b
7
 [975.6]-2 [1126.3]-2 
a
8
-b
8
 [1132.2]-2 n/d 
w2 [650.2]- [650.2]- 
w3 [963.3]- [963.3]- 
w4 [1252.5]- [1252.3]- 
w5 [1541.7]- [770.2]-2 
w6 [915.1]-2 [914.8]-2 
w7 [1079.4]-2 [1230.9]-2 
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Figure 2-9. LC-MS of ds-32 bp exon 7 probe:  (A) Extracted ion chromatogram of singly 
adducted Fragment 3, m/z 1234.4 (B) MSMS spectra of fragment ion m/z, 1234.4 showing the 
obtained an-bn and wn ions. Ions with m/z similar to standard are shown in green and ions with 
increased m/z shown in red 
Figure 2-10. . LC-MS of ds-32 bp exon 7 probe: MS/MS spectrum of 1530.3 showing an-bn and 
wn ions. Ions with m/z similar to standard labeled in green and ions with increased m/z in red in 
10mM Tris buffer, pH 7.4 and 0.1M NaCl 
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Table 2-10. Calculated m/z for standard and singly adducted DNA fragments of fragment 3. 
(m/z highlighted in red were the ions with increased m/z compared to that of standard 
corresponding to BPDE adducted) 
Fragment ion 
m/z 
Unadducted Singly Adducted Fragment 
a
2
-b
2
 [401.1]- [401.1]- 
a
3
-b
3
 [730.2]- [730.2]- 
a
4
-b
4
 [1043.3]- [1043.3]- 
a
5
-b
5
 [1372.4]- [1372.4]- 
a
6
-b
6
 [1702.0]- [1001.3]-2 
a
7
-b
7
 [1007.2]-2 [1158.8]-2 
a
8
-b
8
 n/d [1309.9]-2 
a
9
-b
9
 [1323.8]-2 [1474.9]-2 
w17 [1755.6]-3 n/d 
w18 [1395.6]-3 n/d 
w19 [1477.9]-4 [1242.7]-5 
w20 [1541.7]- n/d 
w21 [915.1]-2 n/d 
 
Since the modification is relatively small in the adducted DNA fragments, we assume the 
adducted and unadducted fragments have only minor changes in electrospray ionization behavior and 
MS response. Relative abundance of specific adducted nucleobases within codons were estimated by 
comparing areas of the extracted ion chromatograms of adducted fragments to that of unadducted 
fragments, and these ratios were further compared with other adducted fragments ratios. Ratios of 
relative amounts of adduction in the 32 bp fragment for codons 248/244 was 1.5 and codons 248/243 
was 1.3 with a relative standard deviation less than 6.5% (n=3). According to p53 handbook 
database,13 the mutation frequency ratio of codons 248/243 is 24, 248/244 is 7, 248/249 is 2.7  and 
248/245 is 2.1. Increased reactivity of codon 243 compared to p53 mutation frequency ratio may be 
related to guanine in codon 243 being the first guanine in our 32 bp fragment which may be more 
available for reaction due to its position near the end of the strand. 
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Table 2-11. Fragments of ds-32 bp exon 7 fragment with corresponding base adducted in 
comparison with the p53 database.13 
Fragment 
Name 
Sequence LC-MS/MS DATA Common Hot Spot 
Database13-15,18  Base Adducted Codon 
Fragment 1 CATGGGCGGC
ATG 
CATG*GGCGGCATG 243 244b, 245a,d 
CATGG*GCGGCATG 244b 244b,245a,d 
Fragment 2 AACCGGAGGC
CCATCCTCA 
AACCG*GAGGCCCA
TCCTCA 
248 248a,b,c,d,e, 249a,b 
Complementary Strands 
Fragment 3 TGAGGATGGGCCTCCGGTTCATG TGAGG*ATGGGCCTCCG
GTTCATG 
Fragment 4 CCGCCCATG CCG*CCCATG 
Note: Possible cancers due to BPDE a. Non Small Cell lung cancer, b. Small Cell lung cancer, c. 
Head and Neck cancer d. Colorectal cancer, e. Skin Cancer 
 
2-5. DISCUSSION 
The 32 bp p53 exon 7 fragment reacted with BPDE had all reactive bases as Gs, and the 
most frequently reacted guanine was in codon 248. Guanines within codons 243 and 244 were 
adducted to a lesser extent. Codon 248 is the major mutation hot spot for most tissue specific 
cancers such as lung, and head and neck. Thus, there is qualitative correlation of the high 
reactive frequency of codon 248 in our fragment with its high rate of mutation in many cancers, 
as well as the observed reactivity of codons 244 and 243. However, the relative mutation 
frequencies of codons 244 and 243 are lower that the relative reactivities we find in the 32 bp 
p53 fragment.  
Differences in reactivity vs. mutation frequency in tumors at codons 244 and 245 is 
undoubtedly related to the complexity of living tumors and cell cultures as compared to our in 
vitro reaction system. In addition to complications from organ-based metabolism, which is 
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absent in our present reactions, differences may be due to DNA being bound to histones and 
other proteins in vivo as well as to in vivo DNA repair. Also, sequences in both 244 and 245 
codons are GGC.  Codon 243 is close to the end of the fragment, adjacent to an AT sequence, 
and may be partially unwound exposing the guanine adjacent to it due to fewer hydrogen 
bonds.49 Codon 243 may thus be more reactive in the fragment than in the full p53 gene. Also, 
under in vivo conditions, a considerable fraction of cytosines are methylated which can mediate 
codon reactivity.50,51 5-Methyl cytosines increase the nucleophilicity of exocyclic amine of 
adjacent guanine as result of inductive electronic effects.52 We are currently exploring this issue 
by additional experiments. 
Covalent binding of BPDE preferentially targets guanines in DNA,53,54 because guanine 
is the best nucleophile of all the DNA bases. The N7 position of guanine is the most nucleophilic 
site but the exocyclic amine group, also a good nucleophile, is the most favorable target for 
polyaromatic hydrocarbon diol epoxides like BPDE. This is because proximity of the N7 group 
to the hydrophilic sugar chain of the DNA makes it less susceptible to attack of hydrophobic 
pyrenyl moieties.55-57 
All exocyclic amines of guanines in single stranded DNA are available for covalent 
reaction with BPDE. In double stranded DNA the exocyclic amines are involved in hydrogen 
bonding with the carbonyl oxygen atom of cytosine hence are not freely available for reactions 
with BPDE. Guanines specifically in the minor groove of duplex DNA can form covalent 
adducts with BPDE, thereby disrupting the hydrogen bonding between the GC base pair.58-60 
As per p53 handbook, codon 247 is a hot spot for Melonoma and Skin Squamous Cell 
Carcinoma, admittedly with a small number of mutations. Although guanine is not in the codon, 
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the potential of BPDE to react with adenine exists. Since we did not find any adduction on any 
nucleobase within codon 247 in our study, selectivity of BPDE to guanines was further affirmed.  
Our results are consistent with the fact that most damaged codons in tumors and cancer 
cell cultures involve guanines as the major site of attack by BPDE.52,53,61 Guanines were also 
exclusive targets in the experiments with ss-oligonucleotides. Structural differences of ssDNA 
and dsDNA may play a role in sequence specific DNA damage. Short single stranded 
oligonucleotides used in our study have a more flexible structure unprotected with a 
complementary strand and featuring a free axis of rotation along the phosphodiester 
backbone.62,63 Thus, while specificity would be expected to be much lower for ssDNA compared 
with that of dsDNA we still find that high mutation frequency codons 249 and 244 are highly 
reactive with BDPE in the short ss-fragments. These results suggest that the relative reactivity of 
the ds-DNA may be a combination of inherent chemistry of the codon sites and the ds- and 
higher structure of the DNA. 
Double stranded DNAs are relatively inflexible due to GC and AT base pairing and 
double helical structure resulting in their complicated secondary and tertiary structures.32 The 
double helical structure also features major and minor groves in duplex DNA. BPDE specifically 
attacks the electron donating exocyclic amine in the minor groove containing the nucleophilic 
GC base pair of DNA. Therefore reactivity of dsDNA will be different to that of ssDNA.58,59 
However in our experiments, we see that the ss-fragments and ds-32 bp fragment both have 
selective reactivity that includes codons with high frequency of mutation in p53. Thus, 
selectivity is different in the ss- and ds-fragments, but still exhibited by the single strands.  
Very few studies thus far have focused on differential selectivity of specific base 
sequences.64 Jernstroem, et. al suggest that guanines adjacent to or flanked by guanines are more 
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reactive64-66 In contradiction, other studies predict that guanines flanked by pyrimidine bases are 
more reactive due to less steric effects as compared to guanines flanked by purine bases.59,67-69 
The reactive site of codon 248 in our 32 bp fragment is a guanine flanked by guanine, while 
codons 244 and 243 are guanines flanked by purine on one side and pyrimidine on the other side 
and show intermediate reactivity. Codon adduction sites in ss-DNA oligonucleotides are 
guanines sandwiched between one purine and one pyrimidine. Hence, our results are in 
qualitative agreement with the predictions quoted above.  However, relating full guanine 
sequence specificity to adjacent bases is undoubtedly an oversimplification, and in addition to 
base sequence, specificity most likely involves complex structural and environmental factors in 
vivo including bound histones and proteins.    
 
2-6. SUMMARY 
In summary, we have described methodology to screen chemicals, drugs and metabolites 
for reactions with oligonucleotides to determine the most frequently adducted nucleobase within 
codons. Results show that LC-MS/MS and restriction enzymes can be used to prepare carcinogen 
modified oligonucleotides so as to identify the site of adduction on oligonucleotide fragments 
longer than 20 base pairs. Our 32 bp fragment reactions represent the first study of a p53 gene 
fragment representing more than 20 base pairs with multiple mutation hot spots. The highest 
reaction frequency was at codon 248, consistent with the highest mutation frequency of the p53 
gene in many cancers. Also, BPDE reactivity found at codons 243 and 244 is consistent with 
these codons being mutated in tissue cancers. Chapter 3 will focus on effect of cytosine 
methylation on rate of BPDE adduction on Exon 7 of P53 gene using LC-MS/MS and Molecular 
modelling. 
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CHAPTER 3 
 
Methyl-Cytosine-Driven Structural Changes Enhance Adduction 
Kinetics of an Exon 7 fragment of the p53 Gene 
 
 
 
3-1. Abstract  
Methylation of cytosine (C) at C-phosphate-guanine (CpG) sites enhances reactivity of 
DNA towards electrophiles. Mutations at CpG sites on the p53 tumor suppressor gene that can 
result from these adductions are in turn correlated with specific cancers. Here we describe the 
first restriction-enzyme-assisted LC-MS/MS sequencing study of the influence of methyl 
cytosines (MeC) on kinetics of p53 gene adduction by model metabolite benzo[a]pyrene-7,8-
dihydrodiol-9,10-epoxide (BPDE), using methodology applicable to correlate gene damage sites 
for drug and pollutant metabolites with mutation sites. This method allows direct kinetic 
measurements by LC-MS/MS sequencing for oligonucleotides longer than 20 base pairs (bp). 
We used MeC and non-MeC (C) versions of a 32 bp exon 7 fragment of the p53 gene. 
Methylation of all 19 cytosines increased the rate constant 3-fold for adduction on G at the major 
reactive CpG in codon 248 vs. the non-MeC fragment. Rate constants for non-CpG codons 244 
and 243 were not influenced significantly by MeC. Conformational and hydrophobicity changes 
in the MeC-p53 exon 7 fragment revealed by CD spectra and molecular modeling increase the 
BPDE binding constant to G in codon 248 consistent with a pathway in which preceding reactant 
binding greatly facilitates the rate of covalent SN2 coupling.  
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3-2. Introduction 
The p53 (or TP53) tumor suppressor gene codes for p53 protein that regulates cell 
division, cell death, genomic stability and suppresses cancer. P53 gene mutations occur in over 
50% of human cancers,1 and are located selectively in exons 5-8, and alter the p53 protein so as 
to minimize cancer protection. Furthermore, mutation sites are clearly correlated with specific 
cancers,2,3 so that prediction of the most reactive p53 codons toward new chemicals and their 
metabolites could be a valuable tool to aid in toxicity and cancer prediction. Within the p53 gene, 
42 CpG sites are methylcytosines (MeC),4,5 and are the most frequently mutated codons or hot 
spots.6,7 Non-CpG MeC related to GC>AT transitions are known in lung, head and neck cancer.  
2,8   
Reactants such as benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE), 7,12-
dimethylbenz(a)anthracene diol epoxide, acrolein,  and mitocin C, are more reactive towards 
MeCpG sites on the genes.4,5 Limited repair of these reacted sites contributes to their role as 
mutational hot spots.  Polyaromatic hydrocarbon (PAHs) metabolites preferentially react with 
MeCpG sites.9 E.g., benzo[a]pyrene is metabolized to BPDE by a sequential pathway involving 
cytochrome P450s and epoxide hydrolase,10,11 and reacts with DNA in SN2 reactions to form 
nucleobase adducts that lead to mutations.12 Previous studies of alkylated CpGs on DNA exon 5 
analogs using [15N3, 
13C1]-labeled guanines and oligonucleotide hydrolysis revealed 2-3 fold 
increases in yields of BPDE adduction for MeCs.13 MeCpG’s also enhanced DNA-acrolein 
adduction 2-fold.14,15 A 21-base pair (bp) oligonucleotide with a CpG site gave MeC-dependent 
voltammetry suggesting enhanced BPDE reactivity.16 A 14 bp oligonucleotide with four MeCpG 
sites gave 3-4 fold increased adduction yields compared to unmethylated CpG.17 In the 1990s, 
Geacintov measured strong non-covalent binding between BPDE and ds-poly(dG-dC).(dG-dC) 
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oligonucleotides and proposed enhanced subsequent coupling with MeCs related to stronger 
binding in a preceding step.18,19 This model was supported by the studies of alkyl-C exon 5 
analogs.13  
We recently reported a restriction-enzyme-assisted LC-MS/MS DNA sequencing method 
that extends reactive codon measurements to ds-DNA lengths longer than 20-bp.20 For a 32 bp 
exon 7 p53 duplex fragment, we found adduct yields for reaction with BPDE in the order of 
codons 248>243>244. In the present paper, we adapt this method for the first time to elucidate 
relationships between codon-specific reaction kinetics with metabolites, and evaluate the 
influence of subtle but important MeC-related p53 gene structure changes on reaction kinetics. 
This approach enabling studies of longer nucleotides that have been previously possible are 
amenable to uncover the influence of important structural changes relevant to the reactivity of 
the entire gene. 
Scheme 3-1. Exon 7 32 bp fragment of p53 gene with major hot spots 244, 245, 248 and 249 
labeled grey, blue, red and green. Restriction enzyme cleavage site CATG in orange a) all-C 
version b) MeC version, all Me except C in restriction enzyme cleavage site. 
 
We compared a MeC form (19 MeCs) with a non-MeC form (Scheme 3-1) of the 32-bp exon 
7 p53 fragment. G in codon 248 CpG had the largest rate constant, which was 3-fold for the MeC 
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version compared to all-C. Rate constants for reactive G’s in non-CpG codons were 5-8 fold 
smaller than codon 248 MeCpG. Conformational and hydrophobicity changes in the MeC-p53 
fragment revealed by circular dichroism (CD) and molecular modeling combine to increase the 
binding constant of BPDE at the codon 248 site to greatly facilitates the rate of the SN2 coupling 
reaction in line with the preceding non-covalent binding pathway. 
 
3-3. Experimental Section 
3-3.1 Chemicals and Reagents. Benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (±) (anti) 
(anti-BPDE) was from National Cancer Institute Chemical Carcinogen Reference Standard 
Repository. Triethylammonium bicarbonate (1.0 M, pH 8.6), HPLC-grade methanol, acetonitrile 
and water were obtained from Sigma Aldrich. Custom made 32 base oligonucleotide fragments 
exon 7 p53 that were methylation on all C’s (MeC) or had no MeCs were from Sigma Aldrich. 
All oligonucleotides were HPLC purified and the mass of non-MeC forward fragment is 9820, 
reverse fragment is 9833 and for the MeC version, forward strand has a mass of 9961 indicating 
the presence of 10 MeC and for reverse strand 9960 indicating the presence of 9 MeC. 
Restriction enzyme NlaIII was from New England Biolabs.  
 
Caution. Benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (±) (anti) (anti BPDE) is a known 
chemical carcinogen. Protective measure like wearing gloves and protective eyewear were taken 
while doing experiment. All experiments were performed in a closed hood. 
 
3-3.2 Reaction of Exon 7 Fragments with BPDE. 100 µg (~5 nmol) of ds-32 base pair exon 7 
fragment is reacted with 50 nmol of BPDE in a total reaction volume of 150 µL, 10mM Tris 
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buffer pH 7.4 and 50 mM sodium chloride in the dark controlled at 25 ± 0.5 C. This reaction 
was performed at various time intervals 2, 4, 6, 8, 12 and 24 hours for both unmethylated C and 
fully MeC versions of the ds-32 base pair exon 7 fragment. Reactions were stopped by adding 
cold acetonitrile and excess BPDE was removed using 3000 da molecular weight cut off filters 
(from EMD Millipore, UFC500396), which allows BPDE to pass through and DNA was 
collected from the filter as described previously.20 These ds-32 base pair P53 gene fragments 
were subjected to restriction enzyme treatment and purification steps before subjected to LC-
MS/MS analysis. All LC-MS/MS samples were run in triplicates.  
 
3-3.3 Circular Dichroism. Circular dichroism experiments on the C and MeC ds-32 base pair 
exon 7 oligonucleotides were performed on Jasco spectrophotometer (J-710), in 10mM Tris 
buffer pH 7.4 and 50 mM sodium chloride. Parameter used within the spectrophotometer include 
sensitivity of 100mdeg, wavelength range 195nm to 230nm with a bandwidth of 5.0 nm. 
 
3-3.4 Restriction enzyme treatment on ds-32 base pair DNA. Approximately 100 µg of ds-32 
base pair was recovered from the reaction mixture and treated with 10 µL (100 units) of NlaIII 
enzyme, 20 µL of 10X NE buffer (from New England Biolabs) and the volume was made up to 
200 µL with water. The reaction mixture was incubated at 37°C for 8 hours. DNA fragments 
were extracted from restriction enzyme reaction mixture using a previously described protocol 
using phenol/chloroform/isoamylalcohol, 25/24/1 and chloroform/isoamylalcohol, 24/1 to 
remove proteins. Briefly mixture of DNA and RE enzymes was vortexed with equal volume of 
phenol/chloroform/isoamyl alcohol for 15 min followed by centrifugation for 10 min, organic 
phase discarded and aqueous phase was collected (for 3 times), and then repeated the same 
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process with chloroform /isoamylalcohol (2 times). Finally the obtained DNA fragments from 
aqueous phase were subjected to desalting using Water’s Oasis HLB cartridges (WAT094226) 
by solid phase extraction. Briefly cartridges were washed with methanol and water for 
equilibration followed by sample addition and washing the salts with 5% methanol and elution 
with 100 % methanol. Obtained samples were evaporated in a rotovap, re-dissolved in water and 
heated and cooled to obtain ss fragments. Stored at -20C until use. 
 
3-3.5 LC-MS/MS Analysis. Thermo Scientific Ultimate 3000 UPLC with Gemini C-18 column 
(0.5 mm ID and 3µ particle size and 150mm length) was used. A binary solvent system with 25 
mM triethyl ammonium bicarbonate as buffer A and 100 % methanol as solvent B was used.  
Separation protocol was 0-3 % B (Methanol) for 3 min, then increased gradient from 3 to 27 % B 
(Methanol) for 24 min, then back to 3 % for 3 min. Between each run a wash is performed with 
gradient from 3% B isocratic for 2 min followed by 3-80 % B for 24 min followed by 
equilibrating back to 3 % for 4 min at 10 µL/min. m-Nitrobenzylalcohol was used via syringe 
pump post column through  three way connector to increase the intensity and charge states of 
oligonucleotide fragments. Absciex Q-Tof and QTRAP 4000 instruments were used in negative 
mode. Product ion scanning was used for qualitative evaluation of site selective of BPDE-DNA 
adduction and multiple reaction monitoring (MRM) was used for the kinetic studies at a 
particular reactive site. For the AB Sciex QSTAR, -4500 ion spray voltage, -130 declustering 
potential and 300C temperature was used with collision energy from -42 to -50 eV for MS/MS 
analysis. MRM on the QTRAP 4000 was done with ion spray voltage of -4500, curtain gas at 45 
units, -115 V declustering potential and collision energy varying from -60 to -80 eV was used. 
All samples were run in triplicate. 
69 
 
The protocol for analyzing the 32 base pair p53 exon 7 fragments was described 
previously. Briefly, restriction enzyme NlaIII is used to cut the 32 bp DNA 4 smaller fragments 
for LC-MS/MS analysis. Product ion scan or collision induced dissociation (CID) was used to 
sequence the oligonucleotides. CID of oligonucleotides gives characteristic an-bn and wn ions. 
Comparing the MS/MS spectrum of un-adducted oligonucleotides with that of adducted 
oligonucleotides determines the exact site of adduction. Fragments obtained after restriction 
enzyme treatment for methylated 32 base pair DNA fragment are shown in Scheme 3-2. 
 
Scheme 3-2.  The four smaller fragments produced after restriction enzyme and heat treatment 
for 32 base pair MeC-exon 7 fragment.  
 
3-3.6 Molecular modeling. A and B form’s of 32-base pair P53 DNA was modeled using make-
na software21 and modified with cytosines methylated using Maestro software and minimized.22 
Solvated models of these modified oligonucleotides were created using CHIMERA software.23,24 
Amber solvation model was used for solvation with a box size of 1Å to accommodate water 
molecules. Autodock 4.2.6 was used for docking studies. Prepared biomolecule (Solvated MeC 
and C 32 base pair exon 7 fragment) were imported into the software.  Lamarckian genetic 
algorithm (LGA) was used in Autodock 4.2.6 to find binding energy between the gene fragments 
and BPDE. Grid or volume for docking studies were kept constant for all the confirmations and 
set to be at maximum. Binding energies, binding constants and the distance between the 
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exocyclic amine of the reactive guanine and epoxide carbon of BPDE were calculated.33   Steps 
for molecular modeling are given below. 
STEPS 
A and B form’s of 32-base pair P53 DNA was modelled using make-na software and 
modified with cytosines methylated using Maestro software and minimized. Solvated models of 
these modified olignucloetides were created using CHIMERA software. Amber solvation model 
was used for solvation with a box size of 1Å to accommodate water molecules. 
Autodock 4.2.6 was used for docking studies. Prepared biomolecule (Solvated MeC and 
C 32 base pair exon 7 fragment) were imported into the software.  Lamarckian genetic algorithm 
(LGA) was used in Autodock 4.2.6 to find binding energy between the gene fragments and 
BPDE. Grid or volume for docking studies were kept constant for all the confirmations and set to 
be at maximum (126X x 126Y x 126Z dimensions). Binding energies, binding constants and the 
distance between the exocyclic amine of the reactive guanine and epoxide carbon of BPDE were 
calculated.25  
Procedure for Docking 
1. Import the biomolecule 
2. Add Hydrogens to the biomolecule  
3. Compute gasteiger charges 
4. Now input the Ligand 
5. Save the output format of the ligand to be in PDBQT (autodock suitable format) 
6. Preparation for grid 
a. Choose Macromolcule (32 bp DNA) 
b. Save as PDBQT 
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c. Choose ligand (from set map types) 
d. Set grid size (maximum grid size used for our study 126 X 126 X 126). 
e. Save out put file as .gpf (grid format for autodock). 
f. Run autogrid from run option. 
7. Docking 
a. Select macromolecule and ligand similar to above from docking menu. 
b. Search Paparmeters given as # of GA runs to be 100, population size 150, 
maximum evaluations 250000, maximumber of generations 27000 and other 
factors kept default. Accept the parameters. 
c. Docking parameter kept default. 
d. Output saved as default. 
e. Run autodock from run menu. 
 
3-4. Results and Discussion 
BPDE was reacted with an exon 7 fragment in solution, the BPDE-adducted 
oligonucleotide is cut by restriction enzyme NlAIII, then denatured by heat to obtain 4 single 
strand (ss) fragments (Scheme 3-1) that were analyzed by LC-MS/MS sequencing. MS/MS 
spectra of undamaged fragments were compare to that of singly adducted fragments to identify 
BPDE-adducted strands (Table 3-1). The extracted ion chromatogram (XIC) for singly adducted 
methylated ss-Fragment 2, m/z 1038.5 z = -6 (Figure 3-1a) shows a single peak, indicating only 
one singly-adducted fragment 2 for the MeC exon 7 fragment. The MS/MS spectrum (Figure 3-
1b) shows an-bn values similar to the undamaged MeC exon 7 up to a5-b5 and an increase in m/z 
from a6-b6 and above indicating adduction on the 5
th base. 
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(AAMeCMeCG*GAGGMeCMeCMeCATMeCMeCTMeCA, * = adduction site). This is confirmed by w 
ions similar to unreacted MeC fragment up to w14 with an increase in w15 (Table 3-2). Similar 
MS/MS spectra were analyzed for Fragment 1. (see Figure 3-2 & Table 3-3. MS/MS spectra 
indicated two positional isomers for singly adducted fragment 1: (MeCATGG*GMeCGGCATG) 
and (MeCATG*GGMeCGGCATG). 
 
Table 3-1. Calculated m/z for fragment 1, fragment 2, fragment 3 and fragment 4 for unadducted 
and singly adducted (increase in mass of 302.323, BPDE) of methylated, unmethylated versions 
of 32 base pair exon 7 fragment. Unmodified cytosine in methylated version shown in red. m/z 
obtained for each fragment is highlighted in bold. 
CATGGGCGGCATG Fragment 1 
z C C Add MeC MeC Add 
1 4014.6 4316.9 4042.6 4344.9 
2 2006.8 2158.0 2020.8 2171.9 
3 1337.5 1438.3 1346.9 1447.6 
4 1002.9 1078.5 1009.9 1085.5 
5 802.1 862.6 807.7 868.2 
6 668.3 718.6 672.9 723.3 
7 572.7 615.8 576.7 619.8 
 
CCGCCCATG, Fragment 3 
Z C C Add MeC MeC Add 
1 2738.8 3041.0 2808.7 3111.0 
2 1368.9 1520.0 1403.8 1555.0 
3 912.3 1013.0 935.6 1036.3 
4 683.9 759.5 701.4 777.0 
5 546.9 607.4 560.9 621.4 
6 455.6 506.0 467.3 517.7 
7 390.4 433.6 400.4 443.6 
8 341.5 379.2 350.2 388.0 
 
 
 
 
AACCGGAGGCCCATCCTCA, Fragment 2 
z C C Add MeC MeC Add 
1 5821.8 6124.1 5933.8 6236.1 
2 2910.4 3061.5 2966.4 3117.5 
3 1939.9 2040.7 1977.2 2078.0 
4 1454.7 1530.3 1482.7 1558.3 
5 1163.547 1224.012 1185.9 1246.4 
6 969.4 1019.8 988.1 1038.5 
7 830.8 874.006 846.8 890. 
TGAGGATGGGCCTCCGGTTCATG, Fragment 4 
Z C C Add MeC MeC Add 
1 7110.6 7413.0 7166.7 7469.0 
2 3554.8 3706.0 3582.8 3734.0 
3 2369.5 2470.3 2388.2 2489.0 
4 1776.9 1852.5 1790.9 1866.5 
5 1421.3 1481.8 1432.5 1493.0 
6 1184.3 1234.6 1193.6 1243.9 
7 1014.9 1058.1 1022.9 1066.1 
8 887.9 925.7 894.9 932.7 
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Figure 3-1. LC-MS/MS of sub-Fragment 2 of methylated version of 32 base pair exon 7 
fragment. a) Extracted ion chromatogram of sub-Fragment 2, m/z 1038.5 with z = -6. b) MS/MS 
spectra of 1038.5 m/z ion eluting at 23.14 min. 
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Table 3-2: MS/MS fragment ions (an-bn and wn ions) for fragment 2 obtained. Increase in m/z 
for an-bn and wn ions indicating BPDE adduction shown in red.  
Ion 
NonMeC  
Fragment 2 
MeC 
Fragment 2 
a2-b2 [490.1]
-1 [490.1]-1 
a3-b3 [803.2]
-1 [803.2]-1 
a4-b4 [1106.2]
-1 [1106.2]-1 
a5-b5 [704.2]
-2 [704.2]-2 
a6-b6 [869.0]
-2 [1020.2]-2 
a7-b7 [1033.6]
 -2 [1184.7]-2 
a8-b8 [1190.2]
 -2 [1341.4]-2 
w13 [1009.8]
-4 [1009.8]-4 
w14 [1092.2]
-4 [1092.2]-4 
w15 [939.4]
-4 [1000.1]-5 
w16 n/d [1060.4]
-5 
w17 n/d [1404.6]
-4 
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Figure 3-2. LC-MS/MS of Fragment 1 of MeC 32 base pair exon 7 fragment. A) Extracted ion 
chromatogram of Fragment 1, m/Z 1085.4 with a charge of -4 B) MS/MS spectra of 1085.4 m/z fragment 
ion eluting at 18.86 min (Peak I) C) B) MS/MS spectra of 1085.4 m/z fragment ion eluting at 19.39 min 
(Peak II) 
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Table 3-3: MS/MS fragment ions (an-bn and wn ions) for fragment 1 obtained. Increase in m/z 
for an-bn and wn ions indicating BPDE adduction shown in red. 
Ion 
NonMeC  
Fragment 
1 
MeC-
Frag1 
Peak 1 
MeC-
Frag1 
Peak II 
a2-b2 [400.1]
-1 [400.1]-1 [400.1]-1 
a3-b3 [713.5]
-1 [713.5]-1 [713.5]-1 
a4-b4 [1017.3]
-1 [1017.3]-1 [1017.3]-1 
a5-b5 [1346.4]
-1 [1346.4]-1 [1649.4]-1 
a6-b6 [837.2]
-2 [988.2]-2 [988.2]-2 
a7-b7 [1002.1]
 -2 [1153.7]-2 [1153.7]-2 
a8-b8 [768.8]
 -3 [869.5]-3 [869.5]-3 
w2 [346.1]
-1 [346.1]-1 [346.1]-1 
w2 [650.1]
-1 [650.1]-1 [650.1]-1 
w3 [963.2]
-1 [963.2]-1 [963.2]-1 
w4 [1252.3]
-1 [1252.3]-1 [1252.3]-1 
w5 [790.2]
-2 [790.2]-2 [790.2]-2 
w6 [954.7]
-2 [954.7]-2 [954.7]-2 
w7 [1106.3]
-2 [1106.3]-2 [1106.3]-2 
w8 [847.2]
-3 [847.2]-3 [847.2]-3 
w9 [955.6]
-3 [1058.2]-3 [955.6]-3 
w10 [1066.6]
-3 n/d [875.1]-4 
w11 [1168.1]
-3 [951.6] n/d 
 
Kinetics. Multiple reaction monitoring (MRM) was then used to quantify BPDE adduction at 
each reactive codon vs. reaction time. Transitions were selected specific to the ss-fragment 
monitored (Table 3-4). For example, transition 1085.4→650.0 for singly adducted MeC 
fragment 1, and 1009.9→650.0 for unadducted fragment 1. Here 1085.4 and 1009.9 are m/z of 
precursor ions of single adducted fragment 1 and unadducted fragment 1, respectively, with 
charge -4. M/z 650.0 represents the product ion of precursor 1085.4 (Figure 3-2 b&c) which is 
also the major transition for the unadducted precursor ion, m/z 1009.9.  
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Table 3-4: MRM Transition selected for quantitation of methylated, unmethylated and single adducted 
version of 32 base pair exon 7 fragment of 53 gene. 
Un Methylated Methylated 
1048->383 = Internal Standard 1048->383 = Internal Standard 
1078.5->650 = Adducted Fragment 1 1085->650 = Adducted Fragment 1 
1003->650 = Fragment 1 1009.9->650 = Fragment 1 
1224>923 = Adducted Fragment 2 890->803 = Adducted Fragment 2 
1163.5->923 = Fragment 2 846.8->803 = Fragment 2 
1184.3->730 = Adducted Fragment 3 1066->650 = Adducted Fragment 3 
1234.6->730 = Fragment 3 1022.9->650 = Fragment 3 
1013->755 = Adducted Fragment 4 1036->650 = Adducted Fragment 4 
912->755 = Fragment 4 935->650 = Fragment 4 
The relative amount of BPDE adduction was measured as ratio of peak area for XIC of 
adducted fragment to total peak area of the corresponding adducted+unadducted fragment. 
Relative amounts of BPDE adduction were plotted vs. time for G’s in codons 248, 244 and 243 
(Figure 3-3a). 
Expressions in eq (1) define k1 as the pseudo-first order rate constant, and k2 as the second 
order rate constant, where Co is initial amount of unreacted exon 7 fragment and C the amount 
unreacted at time t. Linear plots that fit eq 1 were obtained (Figure 3-3b), as shown for codon 
248 for MeC and all C exon 7 fragments. We obtained k1 from the slopes, and k2 from k1 (eq 1).  
ln C = ln Co - k1t  ;    k2 = k1/[BPDE]   (1) 
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Figure 3-3. Kinetic study of BPDE adduction on MeC and all-C 32 bp p53 exon 7 gene 
fragments: a) Relative amount of BPDE adducted to guanine within codons 248, 244 and 243. b) 
Rate plots showing natural log of relative amount of undamaged oligo fragments (ln [A]/[A0]) vs 
time. c) Bar graph showing comparative rate constants k2 (s
-1M-1) calculated from the slope of 
rate plots for BPDE adduction. Error bars represent SD for n=3. 
 
Kinetic results show that k2 for BPDE adduction on codon 248 CpG is nearly 3-fold larger 
for the MeC fragment vs. C-only (Figure 3c, Table 3-5). Rate constants for non-CpG adduct at 
codons 244 and 243, are ~20% smaller for MeC vs C-only, but differences are not statistically 
significant. The k2 ratio of the MeC oligonucleotide for codons 248/244 is ~9, close to ratio of 
mutational frequencies in the p53 gene.2 For MeC exon 7 (Table 3-5)., codon 248/243 k2 ratio is 
5.3 while the mutation ratio is a bit larger at 24. These results demonstrate the influence of MeC 
on CpG sites like codon 248 in the p53 gene to greatly increase reaction rates of MeCpG sites. 
Results show negligible influence of MeC on reactive non-CpG guanines. 
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Table 3-5. Rate constants k1 and k2 and ratios for different reactive sites. 
Rate Constant 
MeC Codon C Codon 
248 244 243 248 244 243 
k1, s
-1 
(x106) 
26±3 3.0±0.7 4.8±1.0 9.0±1.3 4.0±0.7 6.3±0.9 
k2, s
-1M-1 
(x102) 
7.8±1.0 0.9±0.2 1.4±0.3 2.7±0.4 1.2±0.2 1.9±0.3 
Rate Constant Ratios 
Me-C/C Ratio Me-C/Me-C Codon 
 
248/244    8.7 
C-C Codon 
 
248/244        2.2 248 2.9 
244 0.8 
248/243   5.4 248/243    1.4 
243 0.8 
Note. Rate constants k1, for codon 244 and 243 in the methylated fragments are not significantly 
different according to t-test at 95% confidence interval. 
Structural Analysis. Additional studies were aimed at molecular interpretation of the 
kinetics. Circular dichroism (CD) spectra of full MeC and C-only versions of the exon 7 
fragments (Figure 3-4), suggest different conformations. The MeC exon 7 has an intense 
negative CD peak at 210 nm and an intense positive peak near 270 nm similar to a pure A-DNA 
structure,26 but also a minimum near 245 nm characteristic of B-DNA. For the non-MeC exon 7, 
the first minimum is shifted to longer wavelength and is weaker, and a maximum at 265 nm is 
broad, with a shoulder at ~285 nm more characteristic of B DNA26 (Figure 3-4). We interpret 
both CD spectra in terms of mixed A-B DNA structures, with MeC’s driving structure toward the 
A. 
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Figure 3-4. a) Circular dichroism showing transition from A to B form of DNA. Reproduced 
from J. Kypr et. al., Nucleic Acid Research, 2009, 37, 1713-1725. B) Interpretation of CD 
spectra of the P53 exon fragment in terms of A and B-DNA. Results suggest transition from 
mixed A- and B-DNA towards more A-DNA content upon methylation of C’s. 
Molecular Modeling. A and B forms of Me-C and C versions of exon 7 were constructed and 
molecular modeling was done using Autodock software. Structures were solvated with water and 
docked with the most reactive isomer (+)anti-BPDE. BPDE conformations at optimal docking 
sites were in the minor groove close to codon 248 for conformations with the most negative 
binding free energy. Conformations with distances between reactive exocyclic amine of G in 
codon 248 and the epoxide carbon of BPDE less 4.5 Å were considered, due to probability of 
subsequently forming covalent bonds. Optimal binding of BPDE to guanine in codon 248 
(Figure 3-5) gave binding free energies (∆Gb) for B and A conformations (Table 3-6) which were 
used to calculate binding constants (Kb) from Kb = -∆Gb/RT, where R is the ideal gas constant 
and T in Kelvin. Larger Kb’s were found for MeC versions in both A and B form of DNA 
compared to all-C counterparts. For conformations approximating experimental ones, MeC A-
form had 5-fold higher Kb than all-C A-form. Smaller interatomic distances of reactive atoms 
were found in A-form of DNA (Figure 3-5, Table 3-6) indicating better accessibility for BPDE, 
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with the smallest distance for the MeC A-form. Docking studies were also done with (-) anti 
BPDE, which gave qualitatively similar results but less dramatic Kb differences. As a control, we 
modeled BPDE binding to ds-poly(dG-dC).(dG-dC) oligonucleotides with all MeCs and all C, 
and found 5-fold larger Kb for MeC version similar to experimental measurements.
18 Thus, 
modeling of MeC exon 7 fragment as an A DNA structure and all-C version closer to B DNA 
agreed well with a pathway featuring preceding non-covalent binding of BPDE in the minor 
groove near codon 248 that “sets up” subsequent fast SN2 covalent coupling. 
Figure 3-5. a) Models of BPDE docked close to reactive guanine in codon 248 in A and B forms 
of the 32 bp exon 7 p53 fragment in MeC and C versions. Distance is between exocyclic amine 
of reactive G and epoxide carbon in Å. (Water is removed for clarity; solvated models with water 
in SI.) b) Model of Benzo[a]pyrene-r-7,t-8-dihydrodiol-t-9,10-epoxide (+) (anti) 
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Table 3-6. Computed binding free energies, binding constant and distance between exocyclic 
amine of reactive G in codon 248 and epoxide carbon of BPDE. 
DNA Binding Energy kcal.mol-1, ∆G Binding Constant, Kb, M-1, Distance, Å 
B Form-C -3.47 3.48 x 102 4.08 
B Form-MeC -4.10 1.00 x 103 4.24 
A  Form-C -3.84 6.58 x 102 3.88 
A Form-MeC -4.80 3.32 x 103 3.50 
 
It’s very likely that stronger binding to the A DNA-like structure of the MeC exon 7 is 
also influenced considerably by hydrophobic interactions that increase for A DNA-like MeC 
oligonucleotides. An indirect indication of this effect was found in preliminary modeling studies 
without water, in which similar trends were found in Kb for systems in Figure 3-5, but Kb 
differences between A MeC and B all-C forms were much smaller. We thus attribute a part of the 
increases in Kb (Table 3-6) for both the A and B forms of the MeC p53 fragments to the 
hydrophobic influence on water structure that tends to increase affinity of BPDE for the codon 
248 minor groove.  
Our findings of B-like to A-like structural changes for conversion from the CMeC 
exon 7 duplexes are consistent with earlier literature.27,28 Crystalized oligonucleotides are 
predominantly B DNA, but can transition to dehydrated A-forms upon methylation when rich in 
CG regions, and intermediate structures between A and B have been crystallized.29,30 The A form 
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has a wider minor groove that provides better accessibility for BPDE.26 This enables a shorter 
distance for the reactive exocyclic amine of G to the epoxide carbon of BPDE in A-form than in 
B form (Table 3-6). Earlier computations showed that epigenetic modifications alter the structure 
of the DNA making sites of adduction more accessible.31-34 
Methods utilized above provide a straightforward approach to directly study kinetics of 
gene damage reactions. Results suggest that methylcytosines, which predominate in tumor 
suppressor genes,4 and influence the kinetics of SN2 reactions with BPDE mainly at CpG sites of 
tumor suppressor genes. In the p53 exon 7 fragment studied, codons 248, 244 and 243 were the 
reactive sites for MeC and all-C versions. Codon 248, the featuring CpG, gave the fastest 
reaction with the MeC fragment reacting 3-fold faster than the non-MeC version (Table 3-5). CD 
spectra and computation modeling uncovered a change in conformation from a mixed A-B to a 
more A-like duplex structure that drives free-energy for noncovalent binding of BPDE in the 
codon 248 region more negative for the MeC version, due to better access to the minor groove 
site and increased hydrophobicity. The resulting larger kb most likely lowers activation free 
energy to contribute significantly to the faster kinetics of SN2 coupling of BPDE to MeCpG in 
codon 248. The structural change does not significantly influence non-CpG codons 244 and 243 
that have similar kinetics for MeC and C versions. The hydrolysis-free methodology used here to 
measure direct kinetics of damage by metabolites to oligonucleotides longer than 20 bp is 
applicable to correlate gene damage sites for drug and pollutant metabolites with mutation sites. 
We speculate that these longer nucleotides are more amenable than shorter fragments to uncover 
the influence of important structural changes relevant to the reactivity of the entire gene. 
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3-5. Conclusion 
Methodology described is directly adaptable to other chemicals and other tumor 
suppressor gene fragments to investigate kinetics of their DNA damage reactions. Molecular 
dynamics modeling can be used as an auxiliary tool to gain a more complete assessment of the 
chemistry of the associated reaction events. This quantitative methodology can be adapted to 
multiple chemicals and multiple exons across multiple tumor suppressor genes to expanding 
knowledge of genotoxicity chemistry pathways in relation to organ specificity of carcinogenesis. 
Next chapter focuses on development of Magnetic bio-colloid based technology coupled with 
LC-MS/MS for screening chemicals/prodrugs which require metabolic activation to cause DNA 
toxicity and co-relation with organ specific cancer. 
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CHAPTER 4  
 
Assessing p53 Gene Damage from Metabolites at High Throughput 
using Magnetic Biocolloids and LC-MS/MS 
 
 
4-1. Abstract 
Codon specific mutations on p53 tumour suppressor gene are correlated with organ 
specific cancer. Chemical or drug metabolites cause specific codon damage on P53 and thus 
tissue specific cancer can be predicted from the available P53 databases. The majority of 
chemicals or drugs require metabolic activation to form reactive metabolite that cause 
genotoxic effects that can measured as DNA damage. Herein we report a high throughput 96 
well plate magnetic bio-colloid reactor approach with restriction enzyme-assisted LC-
MS/MS sequencing to screen chemicals for sequence specific gene damage. Metabolic 
enzymes on the magnetic beads bio-activate test chemical to form metabolites that, if 
reactive enough, react with DNA. Aflatoxin B1 was used as a model compound and 8 
different cyt P450 enzymes from various organ tissues were used to quantitatively determine 
which enzymes play major roles in bioactivation of aflatoxin B1. Cyt P450s convert 
aflatoxin B1 aflatoxin B1-8,9-epoxide which reacts with DNA in an Sn2 reaction to form 
N7-guanine adducts.  These adducts cause depurination and subsequent strand breaks. A 32 
base pair exon 7 fragment of p53 gene was used to reveal abasic sites and a strand break at 
codon 249, correlated to possible liver cancer. Human liver microsomes and cyt P50 3A5 
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supersomes showed highest reactivity for of Aflatoxin B1, estimated by comparing the 
amount of N7-guanine adducts formed from various enzyme sources. Other compounds 
studied include NNK and styrene.  
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4-2. Introduction 
Toxicity screening plays a major role in drug development. Approximate cost to bring a 
new drug into the market is $ 1.7 billion.1,2 Toxicity screening contributes to nearly one third of 
the cost in drug development, but 20-40% of drug candidates fail at the phase III clinical test 
level due to toxicity issues not revealed by prior bioassay and animal toxicity tests.3,4 New, rapid, 
reliable pathway-based screening assays that take in account metabolic activation5 are important 
for improving safety and lowering cost of new drugs and environmental chemicals. 6-
8Genotoxicity refers to damage to genetic material by chemical agents and their metabolites. 8-10 
we developed a restriction enzyme-assisted LC-MS/MS sequencing method to identify reactive 
codons and measure sequence specific reaction rates of codon damage using a p53 tumor 
suppressor gene fragment. to correlate with organ specific cancer and to determine the effect of 
cytosine methylation and kinetics of Benzo[a]pyrene-diolepoxide covalent adduction with 
DNA.11,12, Mutations of p53 have been identified in >50% of human cancers,13 and mutation sites 
are correlated with specific cancers.14,15 For example, mutations of codons 157, 158, 248, 249 
occur in lung cancer, codon 273 in brain and prostate cancer, codons 175, 248 and 273 in breast 
cancer and codons 175, 282, 248, 249 in liver cancer.16 These mutations are located in p53 exons 
5-8, and alter the p53 protein coded by the gene to minimize or eliminate cancer protection. 
Thus, prediction of metabolite reaction sites on p53 codons is a valuable tool to aid in cancer 
prediction related to new chemicals and drugs.17 We report here for the first time the 
combination of  restriction enzyme-assisted LC-MS/MS sequencing with 96 well plate-magnetic-
biocolloid enzyme reactors to determine the effect of reactive metabolite reactions on sequence 
specific DNA damage. The 96-well plate approach hs allows evaluating multiple metabolic 
enzymes simultaneously. Aflatoxin B1 Aflatoxin B1 is a mycotoxin produced by Aspergillus 
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flavus and Aspergillus parasiticus, was used as a model test chemical.   Aflatoxin is a mycotoxin 
present in foods including rice, oil seeds, peanuts, and corn.18 Aflatoxin B1 is metabolically 
converted by cyt P450 enzymes to the DNA-reactive aflatoxin B1-8,9-epoxide that covalently 
binds to the N7 position of guanines.19,20 DNA damage due to aflatoxin B1 metabolites include 
covalent DNA adducts, abasic site formation, strand breaks and oxidative DNA damage. 
Aflatoxin B1 is associated with G-T transversion at codon 249 of P53 gene and is often 
associated with liver cancer.21 
Scheme 4-1. Structure of 32 base pair (bp)  exon 7 probe of the p53 gene extending from codon 
242 to 253. Three mutation hotspot codons 245 (green), 248 (blue) and 249 (red) in various 
cancersError! Bookmark not defined. are highlighted. The NIaIII restriction enzyme site, CATG, is 
shown in purple and four fragments obtained after restriction enzyme and heat and cool 
treatment are labeled in brown. 
The present paper focuses on determining sequence specific DNA damage from in situ 
metabolized aflatoxin B1 on exon 7 probe of P53 gene (Scheme 1). Additional studies were done 
on nicotine-derived nitrosoamine ketone (NNK) and Styrene to demonstrate generality. 
Restrictions enzymes were used to cut the 34 bp p53 sequence into smaller fragments and LC-
MS/MS sequencing was used to determine sequence specificity gene damage. Results for 
aflatoxin B1 show that it is efficiently converted to aflatoxin B1-8,9-epoxide, which reacts manly 
with N7 on the guanine in codon 249, then undergoes depurination (perhaps ralated to heating 
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during the protocol) to form  an abasic site, which also results in a fraction of strand breaks 
adjacent to the abasic site. 
4-3. Experimental 
4-3-1. Chemicals & Reagents 
Aflatoxin B1 (AFB1, MW=312.23), poly(diallyldimethylammonium chloride) (PDDA, 
average Mw= 100,000-200,000), poly(sodium 4-styrenesulfonate) (PSS, average MW= 70000), 
calf thymus DNA, Triethyl ammonium bicarbonate and all other chemicals were from Sigma. 1µ 
carboxylated magnetic particles from Bangs Laboratories. Custom made 32 base pair exon 7 
fragment from codon 242-253 was from Integrated DNA technologies (IDT). Restriction enzyme 
NIaIII was purchased from New England Biolabs. Pooled male human liver microsomes, HLM, 
Human lung micrososmes, Supersomes, 3A4, 2A6, 1B1, 3A5 and 1A2 were obtained from BD 
Gentest. 
Caution. Aflatoxin B1 is a known chemical carcinogen. Protective measure like wearing 
eyewear and gloves were taken while doing experiment. All experiments were performed in a 
closed hood. 
4-3-2. Magnetic Bio-colloid Methodology 
 A high throughput methodology was developed to screen multiple chemicals by multiple 
cytochrome P450 enzyme sources for their potential to cause DNA damage on P53 gene 
fragments. Carboxylated magnetic beads were used on to which layer by layer assembly of 
enzyme sources were made to facilitate simple and easy conversion of prodrugs/carcinogens to 
their reactive metabolites ad their subsequent reaction with P53 gene fragments. Layer by layer 
assembly of PDDA/enzymes was made on magnetic particles in a 96 well plate (Scheme 4-
2).22,23 Briefly 80 µL of 1µM carboxylated magnetic particles (128 mg) were taken and added to 
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120 µL of 10mM Tris buffer pH 7.4. To this 200 µL of 2 mg mL-1 PDDA in water was added 
and incubated on a temperature controlled shaker at 25C for 20 minutes at 800 rpm speed. After 
20 minutes magnetic particles were washed with 10 mM Tris buffer with 50mM NaCl, pH 7.4 
three times. To this magnetic beads 340 µL of 10 mM Tris + 50 mM NaCl buffer, pH 7.4 was 
added to this suspension 60µL of enzyme was added slowly dropwise and incubated at 4C for 
30 minutes on a temperature controlled shaker at 800 rpm speed. After the incubation step the 
beads were washed with 10 mM Tris buffer with 50mM NaCl, pH 7.4 three times. These beads 
were incubated for 4 hours with 150 µM Aflatoxin B1 solution and 150 µg of ds-32 base pair 
exon 7 fragment at 37C in the presence of NADPH regeneration system24 and 10 mM 
Phosphate buffer, pH 7.4.  
Scheme 4-2. Schematic representation of experimental protocol for 96-well plate, magnetic 
biocolloid and restriction enzyme assisted analysis of P53 gene fragments. A) Cytrochrome P450 
assisted conversion of carcinogen/prodrug to reactive metabolite that can cause DNA damage. B) 
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Separation of magnetic beads and filteration to remove small molecules. C) Restriction enzyme 
treatment to cut 53 gene fragments. D) Purification to remove proteins & Salts E) LC-MS/MS 
analysis.  
After the reaction the beads were separated using a magnet and the supernatant 
containing the reacted 32 base pair exon 7 fragment and excess AFB1 was collected (Scheme 4-
2B). 3000 da molecular weight cut off filters (from EMD Millipore, UFC500396) were used to 
remove the small molecules from DNA and small molecule mixture before restriction enzyme 
treatment.  
 
4-3-3. Restriction Enzyme treatment, Protein separation & Desalting 
 Approximately 150 µg of ds-32 base pair DNA was incubated with 15 µL (150 units) of 
NIaIII enzyme in 20 µL of 10 X NE buffer (provided by New England Biolabs) and volume 
made up to 200 µL using water for 8 hours at 37 C. After the reaction is complete, DNA 
fragments were extracted from restriction enzyme reaction mixture using a previously described 
protocol using phenol/chloroform/isoamylalcohol, 25/24/1 and chloroform/isoamylalcohol, 24/1 
to remove proteins.Error! Bookmark not defined. Briefly mixture of DNA and RE enzymes was vortexed 
with equal volume of phenol/chloroform/isoamyl alcohol for 15 min followed by centrifugation 
for 10 min, organic phase discarded and aqueous phase was collected (for 3 times), and then 
repeated the same process with chloroform /isoamylalcohol (2 times). Before subjecting to LC-
MS/MS analysis DNA samples were subjected desalting using solid phase extraction (SPE) 
cartridges (Waters Oasis HLB cartridges, WAT094226). Briefly the cartridges were first washed 
with methanol, followed by water then samples was added and washed with 5% methanol to 
remove salts. The DNA samples were eluted from the cartridges using 100 % methanol. Samples 
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were dried using a roto-vap and dissolved in 100 µL of distilled water. This sample was heated 
and cooled rapidly to convert ds-DNA to ss-DNA and stored at -20 C until use.  For small 
molecule analysis 7-methylguanosine was added to the reaction mixture as an internal standard 
with final concentration to be 0.2 µM. 
 
4-3-4. LC-MS/MS Parameters 
Ion pair reverse phase chromatography is used to separate the oligonucleotides using 25 
mM Triethylammonium bicarbonate as ion pairing agent. A binary solvent system with 25 mM 
Triethylammoniun bicarbonate as buffer A and 100 % Methanol as Buffer B was used. Gemini 
C-18 column (0.5 mm ID, 3 µ particle size and 150 mm length was used along with Thermo 
Scientific Ultimate 3000 UPLC.  Separation protocol was 0-3 % B (Methanol) for 3 min, then 
increased gradient from 3 to 27 % B (Methanol) for 24 min, then back to 3 % for 3 min. Between 
each run a wash is performed with gradient from 3% B isocratic for 2 min followed by 3-80 % B 
for 24 min followed by equilibrating back to 3 % for 4 min at 10 µL/min. Post column m-
Nitrobenzylalcohol was used via syringe pump through  three way connector to increase the 
intensity and charge states of oligonucleotide fragments.25 Absciex QSTAR was used in negative 
mode. Product ion scanning was used for qualitative evaluation of site selective of modification 
of oligonucleotides. Ionization parameters for the AB Sciex QSTAR, -4500 ion spray voltage, 
ion source gas 1 at 30 units and ion source gas 2 at 25 units, -80 V declustering potential, -280 V 
focusing potential and 300C temperature was used with collision energy from -42 to -50 eV for 
MS/MS analysis. All samples were run in triplicate. ThermoScientific, Hypersil gold column 
(C18, 100 mm X 0.3mm id and 3 µ particle size) was used for small molecule analysis. Reverse 
phase chromatography with binary solvent system containing 10 mM Ammonium acetate as 
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buffer A and Methanol as buffer B with 0.2 % Formic acid was used. Separation protocol 
involves 15 min with 5 % B (for 2 min) and %B increased to 70 % (2-12 min) and stabilized 
back to 5 % (12- 15min). Absciex Qtrap 4000 was used for quantitation in positive mode and 
Multiple reaction monitoring was used to quantitate the DNA adducts. Ionization conditions 
include 5000 ion spray voltage, curtain gas at 10 units, ion source gas 1 at 12 and ion source gas 
2 at 5 units & temperature at 200C with collision energy of 45 eV. 
 
 
4-4. Results 
 A 96 well plate based high throughput methodology was developed to screen multiple 
chemicals under the influence of multiple CYT P450 enzyme sources for their biotransformation 
to their reactive metabolites that have potential to cause DNA damage on P53 gene fragments 
that can be correlated with organ specific cancer. CYT P450 enzyme sources from different 
tissue sources (both supersomes and microsomes) like liver, lung, intestine and kidney were used 
to see which of these enzyme sources play a major role in biotransformation of specific drugs. 
Aflatoxin B1, NNK and Styrene are the three carcinogens that are used in this study. 
32 base pair exon 7 fragment of P53 gene was reacted with Aflatoxin B1 in the presence 
of CYT P450 enzymes and NADPH regeneration system. CYT P450 enzymes biotransform 
Aflatoxin B1 to Aflatoxin B1-8,9-epoxide in the presence of NADPH regeneration system. 
Aflatoxin B1-8,9-epoxide reacts with N-7 position of guanine to form covalent adducts, Scheme 
4-3. These adducts are unstable and undergo depurination resulting in the formation of abasic 
site, Scheme 4-4.26 These abasic sites can further undergo β-elimination resulting in strand 
breaks.Error! Bookmark not defined.,27  
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Scheme 4-3. Proposed metabolic pathway for conversion of Aflatoxin B1 to aflatoxin B1-8,9-
epoxide and covalent adduction on N-7 position of guanine. 
 
Scheme 4-4. Proposed mechanism of depurination/base loss from 8,9-dihydro-8-(7-guanyl)-9-
hydroxy-AFB1 (AFB1-N7-Gua) and subsequent strand break via β elimination mechanism. 
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Scheme 4-5. Proposed mechanism of DNA damage effects of Aflatoxin B1 on 32 base pair exon 
7 fragment. 
Restriction enzyme treatment on 32 base pair exon 7 fragment will result in four 
fragments. Calculated m/z for all the fragments were as shown in Table 4-1. Aflatoxin B1 
reacted 32 base pair exon 7 fragment of P53 gene in the present of cytochrome P450 enzymes 
and NADPH regeneration system includes both undamaged and damaged oligonucleotide 
fragments. Mass spec analysis of the reacted sample include undamaged fragment 1 
(m/z=1002.6, z=-4), undamaged fragment 2 (m/z=1163.5 z=-5), undamaged fragment 4 
(m/z=912.7, z=-3), undamaged fragment 3 (m/z=1421.3 z=-5), strand break on fragment 2 
(Scheme 4-5) and abasic site on fragment 1.  
Table 4-1. Calculated m/z for fragment 1, fragment 2, Damaged (Loss of guanine) Fragment 1, 
Damaged Fragment 2 and strand breaks from fragment 2. 
Fragment 1, OH-CATGGGCGGCATG-OH 
Negative 
Charge 
Undamaged Base loss,-G 
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Fragment 2, P-AACCGGAGGCCCATCCTCA-OH 
Negative  
Charge 
Undamaged Base loss, -G 
Strand break 
Fragment 2_1, P-AACCGGAGG-OH Fragment 2_2 
Intact Base Loss, -G Intact 
1.000 5821.771 5671.650 2851.847 2701.726 2986.931 
2.000 2910.381 2835.321 1425.419 1350.359 1492.61 
3.000 1939.918 1889.878 949.943 899.903 994.971 
4.000 1454.686 1417.156 712.205 674.675 745.946 
5.000 1163.547 1133.523 569.563 539.538 596.579 
6.000 969.455 944.435 474.467 449.447 496.981 
7.000 830.817 809.371 406.542 385.096 425.84 
8.000 726.839 708.074 355.598 336.833 372.484 
9.000 645.967 629.287 315.975 299.25 297.785 
 
1.000 4014.656 3864.535 
2.000 2006.824 1931.763 
3.000 1337.546 1287.506 
4.000 1002.908 965.377 
5.000 802.124 772.100 
6.000 668.269 643.249 
7.000 572.658 551.212 
8.000 500.950 482.184 
9.000 445.176 428.460 
10.000 400.558 385.546 
11.000 364.052 350.405 
12.000 333.630 321.120 
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Figure 4-1. LC-MS of ds-32 bp exon 7 probe: (A) Extracted ion chromatogram of singly 
adducted fragment 2-1, m/z 674.4. (B) MSMS spectra of Fragment 2-2 showing the obtained an-
bn and wn ions. Ions with m/z similar to standard are shown in green and ions with increased m/z 
shown in red. 
A more detailed analysis on fragment 2 indicate two fragments of Fragment 2, Fragment 
2_1 and Fragment 2_2, scheme 4-5. Fragment 2_1 m/z=674.4, z=-4. The fragment corresponding 
to this mass is AACCGGAGG with a guanine loss that is AACCGGAG_ difference in mass 
102 
 
between AACCGGAGG and AACCGGAG_ is ~151 daltons corresponding the guanine. 
Position of guanine loss determines by MS/MS analysis as shown in Figure 4-1. CID spectra of 
oligonucleotides give characteristic an-bn and wn ions, comparing the spectra of 
damaged/modifies fragments with that undamaged fragments gives us the exact position of DNA 
damage. For fragment 2_1 all wn ions have m/z less than standard hence base lost is the terminal 
base.  
Figure 4-2. LC-MS of ds-32 bp exon 7 probe: (A) Extracted ion chromatogram of  
(CCCATCCTCA) fragment 2-1, m/z 674.4. (B) MSMS spectra of Fragment 2-2 showing the 
obtained an-bn and wn ions. Ions with m/z similar to standard are shown in green and ions with 
increased m/z shown in red. 
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Fragment 2_2 has an m/z of 994.9, z=-3. This fragment is intact without any base loss 
which is further confirmed by MS/MS analysis. MS/MS spectra of fragment 2-2 is as shown in 
figure 4-2. Presence on all an-bn and wn ions with m/z similar to that of standard CCCATCCTCA 
sequence indicate the depurination at codon 249 leading to a strand break between guanine and 
cytosine. 
Figure 4-3. Product ion scan or MS/MS spectra of 8,9-dihydro-8-(7-guanyl)-9-hydroxy-AFB1 
(AFB1-N7-Gua) adduct showing major peak 152 corresponding to protonated guanine. 
 
In order to study the effect of different enzyme sources on the amount of DNA damage 
by Aflatoxin B1, 8 different CYT P450 enzyme sources are used namely Human liver 
microsomes (HLM), Human Lung Microsomes (HLuM), Human Kidney Microsomes (HKM) 
and Human Intestine microsomes (HIM). In addition to microsomes, supersomes that in rich in 
specific organs were selected namely 1A2 (Liver), 2A6 (Lung), 1B1 (Kidney) and 3A2 
(Liver).28,29,30 Relative amount of DNA damage was estimated by determining the amount 8,9-
dihydro-8-(7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-Gua) adduct formed when using different 
sources of CYT P450 enzymes. 
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Figure 4-4. Quantitative estimation of amount of DNA damage through different enzyme 
sources estimated as a function of amount of N7 guanine adduct formed in the 96 well plate 
magnetic biocolloid reaction by microsomal enzyme sources. A) Selected reaction monitoring 
(SRM) transition chromatogram for 8,9-dihydro-8-(7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-Gua) 
adduct (480 → 152) from magnetic bio-colloid reactors for microsomal enzyme sources (Liver, 
lung, kidney and intestine). B) Bar graph representing the relative amount adducts formed 
calculated as a ration of area under curve obtained from SRM transitions of Guanine adduct to 
that internal standard, 7-Methylguanosine. 
Product ion scan of 8,9-dihydro-8-(7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-Gua) adduct 
is as shown in figure 4-3. MS/MS spectra show two major fragments 152 and 329 corresponding 
to protonated guanine (152) and Aflatoxin B1 alcohol. Multiple reaction monitoring is used to 
quantify the amount of adduct formed using 7-methyl guanosine as an internal standard. MRM 
transitions selected are 480→ 152 for 8,9-dihydro-8-(7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-
Gua) adduct and 298→166 for 7-methylguanosine. Figure 4-4 shows the relative amount of 8,9-
dihydro-8-(7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-Gua) adducts obtained from the ratio of area 
under the curve from extracted ion chromatogram obtained for N7-Guanine adduct transition to 
that of internal standard transition. 
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Figure 4-5 shows the relative amount of 8,9-dihydro-8-(7-guanyl)-9-hydroxy-AFB1 
(AFB1-N7-Gua) adducts obtained calculated as the ratio of area under the curve from extracted 
ion chromatogram obtained for N7-Guanine adduct transition to that of internal standard 
transition. Order of microsomal enzyme reactivity is HLM > HLuM > HIM > HKM. Order of 
relative amount N7 guanine adduct formed by supersomes is 3A5 > 2A6 > 1A2 > 1B1. Overall 
order of relative amount N7 gaunine adduct formation is HLM > 3A5 > HLuM > HIM > 2A6 > 
1A2 > 1B1 > HKM. 
Figure 4-5. Quantitative estimation of amount of DNA damage through different enzyme 
sources estimated as a function of amount of N7 guanine adduct formed in the 96 well plate 
magnetic biocolloid reaction by supersomal enzyme sources. A) Selected reaction monitoring 
(SRM) transition chromatogram for 8,9-dihydro-8-(7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-Gua) 
adduct (480 → 152) from magnetic bio-colloid reactors for supersomal enzyme sources (1A2, 
2A6, 1B1, 3A5). B) Bar graph representing the relative amount adducts formed calculated as a 
ration of area under curve obtained from SRM transitions of Guanine adduct to that internal 
standard, 7-Methylguanosine. 
 
 Abasic site formed on fragment 1 was analyzed by comparing the MS/MS spectra of 
undamaged fragment 1 to that basic site formed fragment 1. Fragment 1 with basic site has an 
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m/z of  956.3, z=-4 which is approximately 151 Da less than undamaged fragment 1 indicating 
the loss of guanine. Comparison of an-bn and wn ions of undamaged vs the damaged fragment 1 
indicate the presence of abasic site at codon 245. CATGGGCGGCATG (undamaged), 
CATGGGC_GCATG (damaged fragment with abasic site). Site of abasic site formed confirmed 
by decrease in a9-b9 and w6 ions and also intact undamaged a8-b8 and w5 ions. 
 Other chemicals were studied to expand the applicability of this study. Chemicals under 
study include styrene and Nicotine derive nitrosoamine ketoke (NNK).  Mass spec analysis of 
NNK and Styrene indicate N7-guanine adducts and abasic site formation whereas 
benzo[a]pyrene-diolepoxideError! Bookmark not defined. indicate covalent adduction of the exocyclic 
amine of guanine. Sequence specificity indicate possible DNA damage events at codon 248 and 
244. 
 
4-5. Discussion 
Drug or environmental chemical induced toxicity is usually associated with either 
overdose or metabolism of the drug/chemical.31 Metabolism plays major role in converting the 
lipophilic or nonpolar molecules to polar usually water soluble metabolites that are excreted out 
of the body. These metabolites are very reactive electrophiles sometime and might cause damage 
to biological molecules like DNA, protein and lipids.32 In this current study magnetic bio-colloid 
based methodology in conjunction with LC-MS/MS has been developed to screen chemicals that 
require bio-activation to become reactive metabolites before causing adverse effects like 
genotoxicity. This methodology has advantages of being high throughput with capability of 
doing 96 reactions simultaneously with multiple enzymes sources and multiple carcinogens. 
Aflatoxin B1 is used as a model compound. Aflatoxin B1 requires metabolic activation to form 
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Aflatoxin B1-8,9-epoxide which forms adduct on the N7 position of guanine in DNA.Error! 
Bookmark not defined.,Error! Bookmark not defined.,33 These N7 guanine adducts can either undergo 
depurination to form abasic site or rearrange to form a more stable formamidopyridine adduct.34 
N-7 Position of guanine is the most nucleophilic site and hence the preferential site for 
DNA alkylation and adduct formation.35,36 N7-Guanine adducts are unstable with half-life’s 
ranging from 2 hours to 150 hours due to addition of positive formal charge on the guanine ring. 
Increase in size of adducts on the N7 position of the guanine decreases their half-life thus making 
them unstable and easier for depurination.37 Abasic site formed can sometimes under strand 
breaks as shown in Scheme 4-3.38 Mechanism of strand break is complex and might involve 
multiple pathways one them being loss of acidic α-proton that is adjacent to the carbonyl in the 
aldehydic form of abasic site leading to strand break via beta elimination of the phosphate 
group.36,39 This reaction is catalyzed by strong nucleophile (ROS species formed by Aflatoxin 
B1) and heat. Aflatoxin B1 also known to cause CYT P450 mediated oxidative DNA damage in 
some cases.34,40 by reactive oxygen species generation the exact mechanism is not known.41 
Abasic site formed on fragment 2 of 32 base pair exon 7 fragment corresponds to codon 
249 which is co-related with liver cancer according to the p53 data base.Error! Bookmark not defined. 
These results were further supported by our multi- enzyme reaction which shown high amount of 
8,9-dihydro-8-(7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-Gua) adducts formed when human liver 
microsomes were used as CYT P450 enzyme source. Among the supersomes 3A5 produced high 
amount of 8,9-dihydro-8-(7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-Gua) adducts suggesting a 
high rate of Aflatoxin B1 biotransformation in liver and intestine.42 Human kidney microsomes 
and 1B1 appear to have low capabilities of metabolite generation which is consistent with our 
previous ECL based assays.Error! Bookmark not defined. 
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Organ specific co-relation can be achieved using this methodology by comparing the 
damaged base within specific codon with tissue specific cancer already present in P53 
database.Error! Bookmark not defined. Our previous study showed site specific covalent adduction at 
codon 248 for benzo[a]pyrenediolepoxide corresponding to lung, head and neck cancer. In our 
current study we established the sequence specific reactivity on codon 249 within the 32 base 
pair exon 7 fragment which is correlated with liver cancer for Aflatoxin B1. This is an exemplary 
in-vitro method that can differentiate sequence specific reactivity as close as one codon 
difference to determine the organ specific cancer.  
This LC-MS/MS methodology in conjunction with 96 well plate magnetic bio-colloid 
technology is high throughput and has the capability to give greater insight on effect of 
chemicals or prodrugs that require metabolic activation to cause DNA damaging effect. In 
addition to being high throughput multiple DNA damaging events can be studied simultaneously 
like covalent adduction, abasic site formation, strand break, oxidative DNA damage, nucleobase 
adduct formation etc.,  
4-6. Summary 
In summary, our restriction enzyme aided LC-MS/MS methodology with magnetic 
biocolloid technology facilitates incorporation of CYT P450 enzyme for bioactivation of 
chemicals with lower reaction times to study the effect of genotoxic potential of 
chemical/prodrugs. We were able to differentiate organ specific cancer between Aflatoxin B1 
and benzo[a]pyrenediolepoxide to be liver cancer and lung cancer respectively based on 
sequence specific DNA damage effects. This methodology can be used to predict the tissue 
specific cancer caused by unknown chemicals or environmental pollutants and also study the 
possible enzymes involved in their metabolic activation. 
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CHAPTER 5 
 
Biosensors for Multiple Prostate Cancer Biomarker Detection 
 
5.1 Abstract  
Point-of-care diagnostics based on multiplexed protein measurements face challenges of 
simple, automated, low cost, high throughput operation with high sensitivity. We developed an 
automated, microprocessor-controlled microfluidic immunoarray for simultaneous multiplexed 
detection of small protein panels in complex samples. A microfluidic sample/reagent delivery 
cassette was coupled to a 30 microwell detection array to achieve sensitive detection of 4 
prostate cancer biomarker proteins in serum. The six-channel system is driven by integrated 
micropumps controlled by an inexpensive programmable microprocessor. An on-board 
microcontroller controls micropumps and reagent flow to the detection chamber according to a 
preset program. Detection employs tripropylamine, a sacrificial reductant, while applying 0.95 V 
vs Ag/AgCl. Resulting ECL light was measured by a CCD camera. Ultralow detection limits of 
10-100 fg mL-1 were achieved in simultaneous detection of the four protein in 36 min. assays. 
While the described method can detect 4 biomarkers simultaneously and our method is one of 
the first reports where automated reagent handling using reagent chambers coupled was 
performed. There is still need for sensors that are inexpensive miniaturized that can be used in 
resource poor settings. Following project uses 3-D printing technology for inexpensive, mass 
production and miniaturized sensors for cancer diagnosis. 
We developed low cost, sensitive, supercapacitor-powered electrochemiluminescent 
(ECL) protein immunoarray fabricated by an inexpensive 3-dimensional (3D) printer. The 
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immunosensor detects three cancer biomarker proteins in serum in 35 min. The 3D-printed 
device employs hand screen printed carbon sensors with gravity flow for sample and reagent 
delivery and washing. The supercapacitor was rapidly photo-recharged between assays using an 
inexpensive solar cell and used to apply voltage to Electro chemical sensor to generate ECL. 
Detection limits were 300-500 fg mL-1 for the 3 proteins in undiluted calf serum. This technology 
could provide sensitive onsite cancer diagnostic tests in resource-limited settings with the need 
for only moderate-level training. 
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5.2 Introduction 
5.2.1 Prostate Cancer & Biomarkers 
Prostate cancer is the most common cancer among men besides skin cancer with current 
annual mortality of more than 27,000 in the United States. About 1 in 7 men are currently 
diagnosed with prostate cancer during their lifetime with about 1 in 39 men will die of prostate 
cancer.1 Current methods in detection of prostate cancer includes direct detection of prostate 
specific antigen (PSA) using gold standard enzyme linked immunosorbent assay (ELISA) 
commonly referred as PSA test, Digital rectal examination (DRE) and biopsy.2 These current 
methods falls behind in terms of sensitivity, specificity and inability to distinguish between 
aggressive and non-aggressive forms of cancer. These imprecise assessments ask for needless 
treatment for the patient leading to deteriorated quality of life and mental health. 
Biomarkers are any measurable or noticeable factors that can indicate a diseased or 
recovery state of a person.3 Biomarkers can also indicate any biological processed or response to 
a treatment. Measuring single markers as in prostate cancer PSA test can lead to false positives 
and false negatives. These markers can be of any type like mutated DNA and RNAs, biological 
processes like cell death and cell proliferation, serum or urine secreted proteins, lipids, small 
molecules etc.4,5 Measuring small panels of these biomarkers can hold tremendous potential in 
early cancer detection and staging of cancer patients for better treatment options.6 In this current 
work we used generalized prostate cancer biomarkers as a panel that include prostate specific 
antigen (PSA), prostate specific membrane antigen (PSMA), platelet factor-4 (PF-4) and 
interlukin-6 (IL-6). 
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5.2.2 Electrochemiluminescence  
 Electrochemiluminescence (ECL) is referred as electrogenerated chemiluminescence that 
involves generation of light emitting species at electrode surfaces, where they involve series of 
electron transfer reactions to generate an excited state of the species that emits light as they reach 
to ground state.7 In general a specified voltage is applied to electrode surface which initiates 
series of reaction where oxidation of the ECL luminophores like ruthenium bipyridine 
(Ru(bpy)3
2+) that emits light at 610 nm and this light can be easily captures on a photomultiplier 
tube (PMT) or a charged couple device (CCD) camera.8   
 
Scheme 5-1. ECL generation mechanism at 0.95 V vs Ag/AgCl when reacted with 
tripropylamine that in turn reacts with RuBPY. Direct oxidation of Tripropylamine (TPrA) on 
the electrode surface to TPrA cation radical which in return forms TPrA radical and H+. TPrA 
radical reacts with [[Ru-(bpy)3]
2+] to generate [[Ru-(bpy)3]
+]. This [[Ru-(bpy)3]
+] reacts with 
TPrA cation radical to generative photo excited [[Ru-(bpy)3]
2+]* that readily generates ECL light 
at 610nm. 
 
STEP 1: TPrA → TPrA•+ + e-
STEP 2: TPrA•+ → TPrA• + H+
STEP 3:
TPrA• + [Ru-(bpy)3]
2+] → [Ru-(bpy)3]
+] + Products
STEP 4:
[Ru-(bpy)3]
+] + TPrA•+ → [Ru-(bpy)3]
2+]* + Products
STEP 5:
[Ru-(bpy)3]
2+]* → [Ru-(bpy)3]
2+] + hʋ (610 nm)
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Usually ECL is generated by reduction of [Ru-(bpy)3]
2+ mediated by oxidation of 
tripropylamine (TPrA) at electrode surface. [Ru-(bpy)3]
2+ used as a label the measured light 
intensity from ECL generated at electrode surface is directly proportional to concentration of 
detecting species in our case it is directly proportional to protein under investigation.9 From 
previous investigations in our lab to avoid direct oxidation [Ru-(bpy)3]
2+ in the particles which 
might show signal from nonspecific binding, an alternative method where a voltage potential of 
0.95 V vs SCE was chosen that causes indirect oxidation of [Ru-(bpy)3]
2+  by TprA resulting in 
ECL,10 See Scheme 5-1. The intensity of ECL light captured by CCD camera is proportional to 
concentration of protein being detected. 
 
5.2.3 Reagent Delivery & Automation  
 Widespread use of diagnostic protein measurements at clinical point-of-care will require 
simple, cheap, fast, sensitive, automated assay devices.11 Critical issues in these systems are cost, 
method complexity, and the need for technically trained operators and frequent maintenance.12 
Immunoassays in general suffer from multiple operations to load samples and add reagents to 
block non-specific binding, remove interferences, and detect target proteins. Significantly 
improved automation is needed to translate immunoassays to point-of-care use.13 A major 
practical challenge involves integrating components into low cost, fully automated devices for 
clinical use. In this work we describe an inexpensive automated multiplexed protein 
immunoarray featuring an onboard microprocessor to control micropumps,14 and a microfluidic 
sample/reagent cassette upstream of a microwell ECL immunoarray. Here we integrated 
electronics, microprocessor platforms, micropumps and microcontrollers with microfluidic 
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components that can handle sample and immunoassay reagents resulting in automated platforms 
for protein detection. 
 
 
5.2.4 3-D Printing 
The recent emergence of inexpensive 3D printers offers revolutionary low cost options 
for designing and constructing biosensor systems.15 Generally 3D printing involves production of 
an object from a computer aided design. The production of an object is achieved by layer by 
layer deposition of material while precisely controlling the position of deposition to achieve 
shape of the object.16 With recent advances there are multiple methods of fabrication techniques 
like fused deposition modeling (FDM)17, stereo lithography (SLA)18, laser sintering etc., that are 
available as desktop printers. Where are multiple varieties of materials are available like regular 
thermo plastics Acrylonitrile butadiene styrene, polylactic acid for food packing for FDM 
printers, acrylate flexible polymers and clear polymers in the form of resins for SLA printers.19 
The printing involves three simple steps 1. Designing a CAD file and transform into printable 
format (splicing format) 2. Uploading instructions to printer and preparing stage for object to 
print. 3. Post treatment steps to remove the object from the platform, smoothen to remove 
roughness, remove any supports used for printing. By using this simple approach, prototyping 
was made easy and scalability was achieved for rapid production of wide variety of prototypes.  
In this work, we reported FDM printer based 3D-printed, gravity flow microfluidic immunoarray 
for multiple protein detection. 
 
5.3 Experimental – Automated Reagent Cassette Delivery  
121 
 
Microfluidic device. Figure 5-1 shows the automated microfluidic immunoarray featuring (i) 
printed-circuit board (PCB)-linked, microprocessor-controlled micropumps, (ii) 6-channel 
sample/reagent delivery cassette, and (iii) 6-channel microfluidic detection array. A PCB circuit 
design was constructed to serve 6 micropumps. Micropumps (Mp6, Bartels) featuring piezo-
actuated membranes were optimized to 155 ± 1.5 µL min-1 by tuning potentiometers for each 
pump. An Arduino microcontroller was used to switch on and off micropumps according to a 
preset program to deliver sample and immunoreagents, and to stop flow for incubations. 
 
 Figure 5-1. Automated microfluidic system featuring 30-microwell detection array connected to 
sample/reagent cassette and PCB-controlled micropumps. An onboard programmed Arduino 
microcontroller runs a micropump program to achieve the assay. 
Sample/reagent delivery cassette was prepared by cutting silicone gaskets (Figure 5-2A) 
using a graft cutter and followed by placing between two machined hard PMMA plates (Figure 
5-2B&C). All the components were assembled with screws to complete sample/reagent delivery 
cassette (Figure 5-2D). The final assembled sample/reagent delivery cassette was 11 in x 5.5 
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inches with six channels, each having 7 loading chambers separated individually by smaller air-
filled channels to ensure delivery of reagents without mixing. The detection chamber also 
features 6 microfluidic channels (60 ± 2 µL) cut from a silicone gasket that is then placed on a 
thin 2 x 3 in PG wafer with computer-printed microwells (Figure 5-2E) made for patterned 6 
channeled silicone gasket from the craft cutter (Figure 5-2F) which the placed on against PMMA 
plate (Figure 5-2G) with PG chip (Figure 5-2H)at the bottom making a sandwiched detection 
microfluidic array. 
 
Figure 5-2. Immunoarray components:  On left, sample/reagent delivery cassette consisting of 
(A) 0.8 mm silicon gasket cut to scale using a KNK cutter, (B) Upper hard PMMA plate 
machined with injection ports, (C) lower PMMA plate and (D) Assembled sample/reagent 
cassette shown with chambers for solutions, assembled with screws. Right panels show detection 
array consisting of (E) PG wafer with computer-printed microwells, (F) silicone gasket cut with 
6 precision channels, (G) top PMMA plate showing attached stainless steel counter electrode on 
top with clear windows for ECL detection and Ag/AgCl reference electrode and (H) fully 
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assembled microfluidic detection array with clear windows in top PMMA plate positioned above 
microwells in each channel. 
Dense SWCNT forests were grown in each microwell (volume 2 ± 0.5 µL)20, Tapping-
mode atomic force microscopy and Raman spectrum confirmed vertical aligned SWCNT forests 
in the microwells with surface roughness 17 ± 4 nm surrounded by the hydrophobic printed wall. 
Terminal carboxylic groups on SWCNTs were activated by freshly prepared 400 mM EDC + 
100 mM NHSS to attach cognate primary antibodies (Ab1) by amidization.  
Once the sample/reagent cassette is loaded with sample, wash buffers, RuBPY-Si-Ab2 
nanoparticles and TPrA, micropumps turn on initially for 55 s to deliver sample to the detector. 
Second, flow is stopped for 20 min to allow analyte proteins in the sample to bind onto Ab1’s in 
microwells. Next, micropumps activate again for 220 s to deliver wash buffer to move sample 
solution and unbound target proteins out of the detection channels. Then, pumps deliver RuBPY-
Si-Ab2 nanoparticles to the detector, and a 900 s stopped-flow incubation follows. Flow then 
turns on to wash away unbound RuBPY-silica nanoparticles. Finally, with the detection chamber 
in a dark box, micropumps deliver TPrA co-reactant to the detection channels, and a potential of 
0.95 V vs. Ag/AgCl is applied for 400 s to generate ECL from RuBPY-Si particles, while a CCD 
camera captures the ECL light. 
 
5.4 Results – Automated Reagent Cassette Delivery 
Relative ECL intensities for the immunoarray with controls (undiluted calf serum) showed spot 
to spot variability of <9 % for n=5 per channel. First and the last channels were used for controls 
and the inner 4 channels were used for detection of the four target proteins. Array to array 
reproducibility of background signals was measured by injecting undiluted calf serum into all six 
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channels giving array to array variability ~11 %. Initially single protein calibrations were 
developed after optimizing the capture and detection antibody concentrations. Calibration studies 
were done by dissolving the four target protein standards in calf serum, which serves as a human 
serum surrogate without human proteins. Channels 1 and 6 in the detection array were used as 
controls, and only undiluted calf serum was introduced into these channels. Channels 2 to 5 were 
assigned for detection of IL-6, PF4, PSMA and PSA, respectively. Simultaneous detection was 
achieved by using a mixture of the 2 RuBPY-Si-Ab2 detection nanoparticles that were each 
decorated with antibodies for 2 of the 4 proteins.  
 
Figure 5-3. Recolourized CCD images of 3 microfluidic immunoarray experiments showing 
reproducibility in simultaneous detection of IL-6, PF-4, PSMA and PSA in calf with respective 
controls at protein concentrations: (A) 10 pg mL-1 (B) 1000 pg mL-1 (C) 5000 pg mL-1. 
 
Increased ECL light with increased concentrations of proteins in the mixture (Figure 5-3). 
Using the average ECL signal divided by the average blank on each chip, we achieved dynamic 
ranges for of 100 fg mL-1 to 1 ng mL-1 for PSA ,100 fg mL-1 to 10 ng mL-1 for PSMA, and 100 fg 
mL-1 to 5 ng mL-1 for IL-6 and PF-4. Nine serum samples from prostate cancer patients and two 
samples from cancer free patients were analyzed and compared with single protein ELISA 
(Figure 5-4). The immunoarray values gave good correspondence with ELISA values. Linear 
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correlation plots of the ELISA vs. immunoarray data gave slopes that were all close to 1.0 and 
intercepts of these plots were within one standard deviation of zero show excellent correlation 
confirming high selectivity and specificity of our assay 
 
Figure 5-4. Correlation plots of ELISA vs. ECL immunoarray for human serum samples for (A) 
IL-6, (B) PF-4, (C) PSA, and (D) PSMA. 
 
5.5 Discussion – Automated Reagent Cassette Delivery 
The developed automated immunoarray showed need for minimal operator attention for 
sensitive, simultaneous quantitative measurements of up to 4 proteins. Once the sample/reagent 
cassette is filled, automated operation and detection takes less than 40 min. Ultrasensitive 
detection in serum was achieved down to concentrations of 10 fg mL-1 over dynamic ranges of 5 
orders of magnitude in concentration. Automation of the methodology is under control of the 
Arduino microcontroller that turns micropumps on and off according to a preset program and 
126 
 
controls the flow of reagents completing immunoassay rapidly. Sample/reagent cassette and 
detection device made by this approach costs just 15$, whereas micropumps and other 
electronics cost 450$. All these components are reusable, making the cost per assay very 
economical. SWCNT forests in detector chip microwells provides a high-area nanostructured 
along multilabel RuBPY-Si-Ab2 nanoparticle provides nearly ½ million RuBPY labels resulted 
in ultrasensitive detection of 4 markers simultaneously. The device is versatile and in principle 
can be reprogrammed for the detection of virtually any small protein panel.  
 
5.6 Experimental – 3-D Printed Arrays 
Commercial desktop 3D Fused Deposition Modeling (FDM) printer, MakerBot 
Replicator 2X, was used and microfluidic immunoarray was printed from polylactic acid (PLA). 
The printer instructions we optimized for optimal printing, heated platform was set to 60 ºC and 
extruder temperature was 230 ºC, with layer height 200 µm. Extruder speed while travelling was 
optimized at 80 mm s-1, whereas speed while extruding was 40 mm s-1. 
Main array printed with 40 mm length x 30 mm width of the base. It has three reagent 
chambers connected to a common downstream microfluidic channel. The reagent chambers 
volume is 170 ± 5 µL that can fill 160 µL microfluidic channel downstream. Under hydrostatic 
pressure the channels were filled with reagents from the reservoirs when in horizontal position. 
The reservoirs are prefilled with sample or reagents through port holes located in custom fit 3D-
printed inserts (Figure. 5-5 A) with rods that seal the outlets of the reservoirs. Flow of sample 
and reagents is controlled by placing the insert to seal the reservoir, or removing it to drain the 
reservoir into the detection channel in a horizontal position. All reagents are prefilled on the 
array, and the operator needs only to release reagents sequentially by removing the inserts. 
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Figure. 5-5 B shows the add-on wash reservoir designed to work with a lever-assisted moving 
platform device that accommodates the sensor array, wash reservoirs and a waste collector at the 
bottom. The wash reservoir was designed to align with reagent reservoirs of the main array and is 
68 mm length x 44 mm width x 26 mm height with capacity of ~1.6 mL buffer. Wash buffer in 
these reservoirs is used to wash off excess sample/reagent from the main array microfluidic 
channels after the immunoassay. Wash reservoirs employ custom fit inserts to turn flow on and 
off similar to the reagent chambers. Normal load position has the detection channel with the 
sensors horizontal. Changing the lever on the wash reservoir to wash position provides a 25º tilt 
angle to the sensor array (Figure. 5-5 B), which enables washing of the immunoreagents to a 
waste chamber at the bottom of the detection channel.  
 
Figure 5-5. 3D-printed main array and wash reservoir module. (A) Basic array showing three 
reagent reservoirs equipped with inserts along with flow path for reagents to reach microfluidic 
channel. (B) Wash reservoir module (5-5B Left) 3D model showing freely moving lever to 
change between wash and load position along with wash reservoirs aligned with main array, (5-5 
B Right) assembled immunoarray setup with both main array and wash module.  
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Supercapacitors (Cellergy, 2.1 V, 80 mF) used to power ECL arrays were low equivalent 
series resistance (ESR) aqueous state electrolyte, high output electrochemical double layer 
capacitors (EDLC’s). A solar panel (Sparkfun, 0.45 W, 94 mA) was used to charge the 
supercapacitor to 1.5 V under ambient room, sun, or iPhone light. Voltage was checked with a 
digital multimeter prior to every experiment to ensure accuracy.  ECL was generated by 
electrochemical oxidation of both tripropylamine (TPrA) and RuBPY on the sensors when 1.5 V 
was applied. 
Assay Procedure: Delivery of sample/reagents from prefilled reservoirs of the main array is 
accomplished by removing the insert top. The reagents flow downstream to fill the detection 
channel. Prefilled wash buffers from wash reservoirs flush the detection channel when the wash 
module lever is adjusted to 25º tilt angle. Individual assay steps are: (1) Release sample from its 
reservoir to fill the detection channel and incubate for 20 min (Figure. 5-6 A) in horizontal load 
position (Figure. 5-6 B). This allows analyte proteins to be captured on Ab1-coated sensors. (2) 
Move platform to wash position (25o tilt) by pushing the lever down, then release wash buffer 
from its reservoir (Figure. 5-6 C). Buffer from the larger wash reservoir passes through the 
sample reservoir into the detection channel and flushes unbound protein to waste (Figure. 5-6 D). 
(3) The platform lever is then returned to the load position, followed by release of Ab2-RuBPY-
SiNPs into the horizontal detection chamber, and incubation for 15 min is allowed to bind to 
previously captured proteins. (4) Wash unbound silica nanoparticles to waste by placing the lever 
in wash position. (5) TPrA solution is released from its reservoir into the horizontal detection 
channel, the array is placed under the CCD camera in a dark box and potential of 1.5 V vs. 
Ag/AgCl is applied with the supercapacitor to generate ECL for 60 s. Acquired ECL images are 
then processed by software to estimate light intensities from each microwell on the array. 
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Figure 5-6. Details of the assay procedure: (A) Cartoon showing removal of insert for sample 
delivery from reservoir by gravity flow. (B) Load position shown with blue food color solution 
filling the horizontal detection channel with lever up. (C) Cartoon showing buffer delivery from 
wash reservoir to detection channel for washing away unbound proteins (inset shows sandwich 
immunoassay on sensors). (D) Wash position showing blue food color solution delivered from 
wash reservoir to main array when lever is down for 25º tilt of detection channel.  
 
5.6 Results – 3-D Printed Arrays 
Reproducibility of array sensors was evaluated at 0 and 500 pg mL-1 for the 3 protein 
analytes. Variation in relative ECL intensities was ≤ 7 % (n=3) array-to-array and ≤10 % spot-to-
spot (n=9). Out of four sensors on the array, sensors 1, 3 and 4 were used for specific protein 
detection. Sensor 2 at the center was used to measure background for each array, and was coated 
with 1 % casein only. Calibrations were done for all 3 proteins individually in calf serum, with 
relative standard deviations ≤ 13 %. supercapacitor mounted on a printed circuit board (PCB), 
connected to the array inside a dark box to generate ECL showed increase in ECL response with 
increase in concentration of proteins (Figure 5-7 A). Multiplexed calibration curves were 
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obtained by assigning sensor 1 to detect PSA (Figure. 5-7 B), 2 to background, 3 to PSMA 
(Figure. 5-7C) and 4 to PF-4 (Figure. 5-7 D). 
 
Figure 5-7. Calibration data in undiluted calf serum showing influence of biomarker protein 
concentration on ECL response: (A) Recolorized ECL images of 8 arrays with showing increase 
in ECL intensity with increased concentration. ECL signals digitized for (B) PSA, (C) PSMA 
and (D) PF-4 in calf serum. Error bars show standard deviation for n = 4. 
 Dynamic ranges were from 500 fg mL-1 to 10 ng mL-1 for all protiens and detection limits 
as 3 times the standard deviations of zero protien controls were 300 fg mL-1 for PSA, 535 fg mL-1 
for PSMA and 420 fg mL-1 for PF-4. Assay validation was done using 4 prostate cancer patient 
serum samples and 2 cancer free human samples using the calibration curves. Linear correlation 
plots obtained for ELISA vs. ECL immunoarray data had slopes close to 1.0 & intercepts of 
these plots were close to zero consistent with good correlation (Figure 5-8). 
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Figure 5-8. Linear correlation plots of ECL vs. ELISA validation studies for (A) PSA, (B) 
PSMA and (C) PF-4. 
 
5.7 Discussion – 3-D Printed Arrays 
Developed inexpensive, portable, 3D-printed ECL immunoarray capable of measuring 
three proteins simultaneously. The cost per assay is ~€0.50 when the arrays are re-used with the 
replaceable sensor chip. The platform utilizes simple steps to complete the immunoassay in 35 
min without external equipment except a CCD camera. Excellent correlation between ELISA 
and the ECL arrays along with relatively small array-to-array standard deviations indicates 
potential for future clinical applications. Considering all costs for immunoreagents, a single 
immunoassay costs ~$1.20, considering the entire platform ($0.90) to be disposable, or ~$0.50 if 
the wash module is reused. Solar panels allowed rapid light-driven charging to 1.5 V of the 
supercapacitor power source to drive the ECL generation step. Integration of this small power 
source on the immunoarray helps make it portable, avoids potentiostatic equipment, and makes 
the assay simpler for the operator. 
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